---
document_datetime: 2023-09-21 19:29:33
document_pages: 60
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/venclyxto-h-c-4106-ii-0008-epar-assessment-report-variation_en.pdf
document_name: venclyxto-h-c-4106-ii-0008-epar-assessment-report-variation_en.pdf
version: success
processing_time: 62.4115433
conversion_datetime: 2025-12-27 16:05:55.932387
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

20 September 2018 EMA/CHMP/717199/2018 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Venclyxto

International non-proprietary name: venetoclax

Procedure No. EMEA/H/C/004106/II/0008

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

+44 (0)20 3660 6000

Facsimile

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................6                                                           |
|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation                                                                                                      | ..................................................................................................6       |
| 1.2. Steps taken for the assessment of the product.........................................................7                |                                                                                                           |
| 2. Scientific discussion                                                                                                    | ................................................................................7                         |
| 2.1. Introduction.........................................................................................................7 |                                                                                                           |
| 2.2. Non-clinical aspects                                                                                                   | ..............................................................................................9           |
| 2.3. Clinical aspects                                                                                                       | ....................................................................................................9     |
| 2.3.1. Introduction......................................................................................................9  |                                                                                                           |
| 2.3.2. Pharmacokinetics...............................................................................................9     |                                                                                                           |
| 2.3.3. Pharmacodynamics..........................................................................................12         |                                                                                                           |
| 2.3.4. PK/PD modelling..............................................................................................13      |                                                                                                           |
| 2.3.5. Discussion on clinical pharmacology...................................................................13             |                                                                                                           |
| 2.3.6. Conclusions on clinical pharmacology.................................................................14              |                                                                                                           |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................15      |
| 2.4.1. Dose response study(ies)                                                                                             | .................................................................................15                       |
| 2.4.2. Main study(ies)                                                                                                      | ...............................................................................................15         |
| 2.4.3. Discussion on clinical efficacy............................................................................34        |                                                                                                           |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................36          |                                                                                                           |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................36    |
| 2.5.1. Discussion on clinical safety                                                                                        | ..............................................................................46                          |
| 2.5.2. Conclusions on clinical safety ............................................................................47        |                                                                                                           |
| 2.5.3. PSUR cycle                                                                                                           | .....................................................................................................47   |
| 2.6. Risk management plan........................................................................................47         |                                                                                                           |
| 2.7. Update of the Product information ........................................................................54           |                                                                                                           |
| 2.7.1. User consultation.............................................................................................54     |                                                                                                           |
| 3. Benefit-Risk Balance..............................................................................55                     |                                                                                                           |
| 3.1. Therapeutic Context ...........................................................................................55      |                                                                                                           |
| 3.1.1. Disease or condition.........................................................................................55      |                                                                                                           |
| 3.1.2. Available therapies and unmet medical need.......................................................55                  |                                                                                                           |
| 3.1.3. Main clinical studies                                                                                                | .........................................................................................55               |
| 3.2. Favourable effects                                                                                                     | ..............................................................................................55          |
| 3.3. Uncertainties and limitations about favourable effects.............................................56                  |                                                                                                           |
| 3.4. Unfavourable effects...........................................................................................56      |                                                                                                           |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | .........................................57                                                               |
| 3.6. Effects Table......................................................................................................57  |                                                                                                           |
| 3.7. Benefit-risk assessment and discussion.................................................................57              |                                                                                                           |
| 3.7.1. Importance of favourable and unfavourable effects..............................................57                    |                                                                                                           |
| 3.7.2. Balance of benefits and risks.............................................................................58         |                                                                                                           |
| 3.7.3. Additional considerations on the benefit-risk                                                                        | balance ...........................................58                                                     |
| 3.8. Conclusions                                                                                                            | .......................................................................................................58 |

<div style=\"page-break-after: always\"></div>

## 4. Recommendations .................................................................................  59 5. EPAR changes  ........................................................................................  60 6. Attachments ..........................................................................................  60 7. Appendix ...............................................................................................  60

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| AE       | adverse event                                              |
|----------|------------------------------------------------------------|
| ALC      | absolute lymphocyte count                                  |
| ASO- PCR | allele-specific oligonucleotide polymerase chain reaction  |
| BCRi     | B-cell receptor pathway inhibitor                          |
| BR       | bendamustine in combination with rituximab                 |
| CCOD     | clinical cutoff date                                       |
| CLL      | chronic lymphocytic leukemia                               |
| CMH      | Cochran - Mantel - Haenszel                                |
| CR       | complete remission                                         |
| CRi      | complete remission with incomplete bone marrow recovery    |
| CT       | computed tomography                                        |
| DLBCL    | diffuse large B-cell lymphoma                              |
| DOR      | duration of response                                       |
| ECOG     | Eastern Cooperative Oncology Group                         |
| EFS      | event-free survival                                        |
| EOCTR    | end of the combination treatment response                  |
| EORTC    | European Organisation for Research and Treatment of Cancer |
| E-R      | exposure response                                          |
| FC       | fludarabine and cyclophosphamide                           |
| FDA      | U.S. Food and Drug Administration                          |
| HBsAg    | hepatitis B surface antigen                                |
| HIV      | human immunodeficiency virus                               |
| HR       | hazard ratio                                               |
| HRQoL    | health-related quality of life                             |
| IRC      | Independent Review Committee                               |
| IV       | Intravenous                                                |
| iwCLL    | international workshop on Chronic Lymphocytic Leukemia     |
| K-M      | Kaplan-Meier                                               |
| MDASI    | M. D. Anderson Symptom Inventory                           |
| MRD      | minimal residual disease                                   |
| MTD      | maximum tolerated dose                                     |
| NHL      | non-Hodgkin's lymphoma                                     |
| nPR      | nodular partial remission                                  |
| OR       | overall response                                           |
| ORR      | overall response rate                                      |
| OS       | overall survival                                           |

<div style=\"page-break-after: always\"></div>

PD

PFS

PK

popPK

PR

PRO

QD

QLQ-

C30

RP2D

R/R

SAE

SCE

SD

SLL

TLS

TTNT

TTP

V+R

progressive disease progression-free survival Pharmacokinetic population PK partial remission patient-reported outcome once daily Quality of Life Questionnaire Core 30 recommended phase 2 dose replapsed/refractory serious adverse event Summary of Clinical Efficacy stable disease small lymphocytic lymphoma tumor lysis syndrome time to next anti-CLL treatment time to tumor progression venetoclax in combination with rituximab

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, AbbVie Deutschland GmbH &amp; Co. KG submitted to the European Medicines Agency on 8 January 2018 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of Indication to include Venclyxto in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. As a consequence, sections 4.1, 4.2, 4.8, 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance.

This submission also fulfils the Annex II condition to submit the results of the MURANO study comparing venetoclax plus rituximab to bendamustine plus rituximab in patients with relapsed/refractory CLL. In addition, RMP version 3.0 is submitted.

The requested variation proposed amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP).

Venclyxto, was designated as an orphan medicinal product EU/3/12/1080 on 11 th  November 2012. Venclyxto was designated as an orphan medicinal product in the following indication: Treatment of chronic lymphocytic leukaemia.

The new indication, which is the subject of this application, falls within the above mentioned orphan designation.

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) CW/1/2011 on the granting of a class waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

<div style=\"page-break-after: always\"></div>

## Protocol assistance

The applicant sought Protocol Assistance at the CHMP on clinical aspects.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Filip Josephson

Co-Rapporteur:

N/A

| Timetable                                                                                                                                              | Actual dates      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| Submission date                                                                                                                                        | 8 January 2018    |
| Start of procedure:                                                                                                                                    | 27 January 2018   |
| Rapporteur's preliminary assessment report circulated on:                                                                                              | 23 March 2018     |
| Co-Rapporteur's preliminary assessment report circulated on:                                                                                           | 23 March 2018     |
| Joint Rapporteur's updated assessment report circulated on:                                                                                            | 20 April 2018     |
| Request for supplementary information and extension of timetable adopted by the CHMP on:                                                               | 26 April 2018     |
| MAH's responses submitted to the CHMP on:                                                                                                              | 20 July 2018      |
| Rapporteur's preliminary assessment report on the MAH's responses circulated on:                                                                       | 21 August 2018    |
| Rapporteur's updated assessment report on the MAH's responses circulated on:                                                                           | 13 September 2018 |
| PRAC RMP advice and assessment overview adopted by PRAC:                                                                                               | 6 September 2018  |
| CHMP opinion:                                                                                                                                          | 20 September 2018 |
| The CHMP adopted a report on similarity of Venclyxto with Arzerra (ofatumomab), Gazyvaro (obinutuzumab) and Imbruvica (ibrutinib) on date (Appendix I) | 20 September 2018 |

## 2. Scientific discussion

## 2.1. Introduction

Venetoclax is a selective, orally available, small molecule inhibitor designed to bind competitively to Bcell lymphoma-2 (BCL-2), thereby liberating pro-apoptotic proteins to trigger apoptosis in cancer cells. Aberrant expression of BCL-2 is common in chronic lymphocytic leukaemia (CLL) and CLL cells typically rely on BCL-2 for survival.

Chronic lymphocytic leukemia (CLL) is a progressive hematologic disease characterized by an accumulation of monoclonal mature B cells in the blood, bone marrow, and secondary lymph organs,

<div style=\"page-break-after: always\"></div>

and diagnosis requires the presence of ≥5000 B-lymphocytes/µL in the peripheral blood for the duration of at least 3 months. It is the most common form of adult leukaemia in the Western world, representing about 30% of leukaemias, with higher incidences in North America and Europe than in Asia, with an incidence of 4 per 100,000 persons per year. In Europe, the age-standardised CLL incidence rate from the United Kingdom Clinical Practice Research Datalink was 6.2/100,000 person years. The median age of diagnosis in the EU is 72 years and only 10% of patients are less than 55 years old. The current WHO classification system recognizes and groups CLL and small lymphocytic lymphoma (SLL) as the same biological entity, with CLL clinically manifesting primarily in bone marrow and peripheral blood, and SLL primarily manifesting in the lymph nodes.

Current treatments for CLL are not curative. Fewer patients obtain responses with each subsequent regimen, and subjects become increasingly resistant to available therapy. Patients who relapse after a disease-free period of over 1 year (2-3 years for chemoimmunotherapy) are considered treatment sensitive and may be candidates for treatment reinitiation. Patients who relapse after a shorter interval, or are refractory to first-line treatment, present a more challenging group, particularly those who are older, have comorbid conditions, and/or harbour high-risk cytogenic abnormalities. A retrospective analysis of patients in the German CLL8 trial found that overall survival after the start of salvage treatment among patients whose disease had progressed within 2 years after the end of chemoimmunotherapy was about 2 years, comparable to that of truly refractory patients. In the EUROCARE-5 registry, the survival rate for patients with CLL at 5 years post diagnosis was 69.0%.

Patients with a genetic mutation with 17p del or a mutation of the tumour suppressor gene TP53 have a poor prognosis, with a median overall survival (OS) of 2 to 5 years. Approximately 5% to 10% of patients with early stage CLL have a 17p del and/or TP53 mutation; this rate increases with treatment lines up to 40% in advanced refractory CLL. Approximately 80% of CLL patients with a 17p del also have a mutation in TP53; sole TP53 mutations in the absence of 17p del have been reported to occur in approximately 4% to 5% of patients.

The monoclonal antibody ofatumumab, is currently approved in the EU in the treatment of CLL in the relapsed or refractory setting as a single agent. The combination of the monoclonal antibody rituximab with chemotherapy (eg, fludarabine and cyclophosphamide) (FCR regimen) is approved in the EU for use in this setting. Marketing authorization for alemtuzumab, which had been indicated for the treatment of CLL in patients for whom fludarabine combination chemotherapy is not appropriate, was withdrawn in the EU in August 2012.

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only treatment option with the potential to cure CLL; however most patients are not fit for HSCT and the benefits must be weighed against the risks for each patient. Historically, the prognosis for 17p del CLL patients has been poor due to the limited efficacy of immunotherapy and chemoimmunotherapy-based regimens.  A median progression free survival (PFS) of 14 months has been reported in first-line 17p deletion patients and 6 to 7 months in relapsed/refractory (R/R) 17p del patients; median OS was approximately 24 months.

Recent introduction of targeted therapy, such as BCR inhibitors (BCRi), has improved the treatment options for CLL patients with the 17p del or TP53 mutation.  Ibrutinib demonstrates independent review committee (IRC) assessed objective remission rate (ORR) of 48% to 65% (investigator assessed ORR of 83% to 86%) and idelalisib/rituximab demonstrates IRC assessed ORR of 85%. In 2014, Imbruvica (ibrutinib) and Zydelig (idelalisib) in combination with rituximab were approved for treatment of CLL patients that have received at least one prior therapy and first-line treatment in the presence of 17p del or TP53 mutation in patients unsuitable for chemo-immunotherapy.

Venclyxto in monotherapy is currently conditionally licensed for the treatment of CLL:

<div style=\"page-break-after: always\"></div>

- in the presence of 17 p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor, or
- in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.

This is an extension of Indication to include: 'Venclyxto in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy'.

Venclyxto is orally administered presented as film coated tablets proposed as a starting dose of 20 mg once daily for 7 days, to be gradually increased over a period of 5 weeks up to the recommended daily dose of 400 mg.

The MAH requested scientific advice (protocol assistance) and follow up advice on clinical aspects of this application.

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

## 2.3.2. Pharmacokinetics

## Venetoclax observed PK

Pharmacokinetic (PK) measurements were taken in both study M13-365 and study GO28667. The PK samples were collected after the venetoclax dose ramp-up schedule. The pre-dose sample for Cycle 1 was collected prior to the first dose of rituximab, whereas all subsequent PK samples were collected after initiating rituximab therapy. A comparison of cycle 1 and cycle 4 pre-dose steady-state mean venetoclax plasma concentration is shown in Table 1 .

<div style=\"page-break-after: always\"></div>

Table 1: Cross-Study Comparison of Steady-State Mean ( ± SD) Venetoclax Plasma Pre-dose Concentrations (μg/mL) Following a 400 mg Dose of Venetoclax

| Study    | Steady-Statemean(±SD)VenetoclaxPlasma Predose Concentrations (μg/mL) Following a 400mgDoseofVenetoclax   | Steady-Statemean(±SD)VenetoclaxPlasma Predose Concentrations (μg/mL) Following a 400mgDoseofVenetoclax   |
|----------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
|          | Cycle 1 a, b                                                                                             | Cycle 4 a, b                                                                                             |
| M13-365c | 0.72±0.49 (n=13)                                                                                         | 0.63±0.58 (n=12)                                                                                         |
| GO28667  | 0.63 ±0.54 (n=151)                                                                                       | 0.68 ±0.75 (n=112)                                                                                       |

## PopPK venetoclax

PK parameters of venetoclax were characterized using a popPK analysis. The popPK analysis assessed whether a previous popPK model structure for venetoclax was able to describe PK of venetoclax in combination with Rituximab in study GO28667. All patients in Arm A (venetoclax + rituximab) in study GO28667 with at least one quantifiable plasma venetoclax concentration value by the pharmacokinetic samples analysis data cut-off date (2/24/2017) were included in the population pharmacokinetic analysis. The analysis included 600 quantifiable venetoclax plasma samples from 182 patients following 400 mg daily dose of venetoclax.

The data were described by the two-compartment population PK model with first-order absorption and elimination. The final model structure was identical to the final model of the previous analysis, with an additional effect of geographical region on apparent clearance. Shrinkage of the inter-individual random effects was moderate to high (31-54%). Rituximab co-administration was estimated to increase CL/F by 7% (95% CI: 2% - 12%). Patients from Central and Eastern Europe and Asia had apparent clearance 30% (95% CI: 21% - 39%) lower and steady state exposure approximately 43% higher compared to patients from other regions.

<div style=\"page-break-after: always\"></div>

Figure 1: Prediction-Corrected Visual Predictive Check, Model 027 (Final Model)

Points are prediction-corrected venetoclax concentrations plotted versus time after most recent venetoclax dose. The lines show median (red), and the 5t and 95* percentiles (blue) of the prediction-corrected venetoclax concentrations. The shaded regions show the 90% confidence intervals on these quantities obtained by simulations. The simulated values were computed from 500 trials with dosing, sampling, and the covariate values of the analysis dataset.

## Prediction-Corrected VPC

<!-- image -->

Source: 027PredCorr\\_Ranges\\_05\\_95.png

Patients from Central and Eastern Europe and Asia had apparent clearance 30% lower and steady state exposure approximately 43% higher compared to patients from other regions. Only 4 patients were from Asia, thus no conclusion on PK differences for patients from the Asian region can be drawn.

60 patients were from central/eastern Europe. However it does not appear that a link for this geographical region to race can be made that would explain the difference in clearance. In the popPK

<div style=\"page-break-after: always\"></div>

report 176 patients were assigned race white while 6 patients were assigned as Asian. No other races were reported.

Both the popPK and the observed data suggest that there is no DDI between venetoclax and rituximab. The similarity in parameter estimates between the previous and the updated popPK models show that PK of venetoclax is similar in study GO28667 compared to what has previously been reported.

## Rituximab PK

PK samples for rituximab were not collected in study GO28667 but were collected in study M13-365. The mean (SD) for serum concentration of rituximab for cohorts 3 through 6 obtained at the monthly combination visits prior to and immediately after the infusion are presented in Figure 2 . Different doses of venetoclax from Cohorts 3 through 6 (200, 300, 400 and 600 mg) did not have any statistically significant impact on rituximab mean concentrations prior to and immediately after infusion at each combination therapy visit (p-value &lt; 0.05). Steady-state (Month 6) mean rituximab trough concentrations ranged from 94.9 - 141 μg/mL, depending on cohort. These are similar to trough values reported in the literature with the same rituximab dosing regimen in R/R CLL patients, with mean rituximab trough concentrations at Month 6 of around 100 μg/mL (Li et al., J Clin Pharmacol. 2012). Mean rituximab trough concentrations at the early cycles, such as at Month 3, are approximately 2 to 3 -fold higher than that reported in the literature, likely due to early reduction of B-cells by venetoclax.

Figure 2: Mean ( ± SD) Rituximab Serum Concentrations prior to and Immediately after Infusion at Monthly Visits: Cohorts 3 to 6

<!-- image -->

## 2.3.3. Pharmacodynamics

No additional studies on pharmacodynamics were submitted.

<div style=\"page-break-after: always\"></div>

## 2.3.4. PK/PD modelling

The post-hoc estimates of venetoclax PK parameters from the final population PK model and the relevant PK covariates for each subject were used to estimate individual exposure measures for each patient. For subjects who did not have evaluable PK data and were not included in the population PK analysis, the PK parameters were imputed using the population estimates and the individual subject's covariate values.

## Exposure-efficacy analysis

The exposure-efficacy analysis utilized 194 patients administered venetoclax from V+R arm of Study GO28667. The exposure-efficacy analysis of venetoclax efficacy parameters showed no statistically significant or clinically meaningful relationships with venetoclax exposure, supporting the current QD 400 mg regimen of venetoclax in combination with rituximab in R/R CLL patients.

## Exposure-safety analysis

The main exposure-safety analysis, which only analyzed the AE data after the end of the ramp-up phase, utilized 191 patients from V+R arm of Study GO28667 and 48 patients from Study M13-365. The logistic regression analyses in patients from studies M13-365 and GO28667 indicated that there were no statistically significant associations between venetoclax exposure and probability of treatmentemergent Grade ≥ 3 neutropenia and treatmentemergent Grade ≥ 3 infections. The pooled exposuresafety analysis suggested no statistically significant improvement in the safety profile would be expected with lower venetoclax exposure over the tested venetoclax dose range (200 - 600 mg QD). Venetoclax co administration did not appear to impact the delivery of rituximab, and patients with higher venetoclax exposure showed similar tolerability of the study treatment compared to patients with lower venetoclax exposure. There was no apparent correlation between venetoclax exposure and venetoclax or rituximab dose intensity. Overall, the exposure safety/tolerability parameters showed no statistically significant or clinically meaningful relationships with venetoclax exposure, supporting the current QD 400 mg regimen of venetoclax in combination with rituximab in R/R CLL patients.

## 2.3.5. Discussion on clinical pharmacology

The observed mean steady state pre-dose concentration for venetoclax at cycle 1 (venetoclax alone) and cycle 4 (venetoclax + rituximab) are all similar in both the M13-365 and the GO28667 studies. This suggests that there is no drug-drug interaction (DDI) between venetoclax and rituximab affecting venetoclax PK. This is further supported by the popPK analysis.

The previous popPK model structure, used as a starting point here, has previously been assessed and deemed adequate. The pcVPC for the updated model show that the model structure is adequate also for the new data from the GO28667 study. The parameter estimates between the previous model and the updated model are small. Shrinkage was however relatively high.

Rituximab co-administration was estimated to increase CL/F by 7% which can be considered negligible.

Rituximab exposures at steady state did not appear to be affected by different doses of venetoclax in study M13-365. Mean rituximab trough concentrations at the early cycles were a 2 to 3 -fold higher

<div style=\"page-break-after: always\"></div>

than that reported in the literature. The explanation that this is likely due to early reduction of B-cells by venetoclax is accepted. Mean concentrations of rituximab at early cycles are still lower than at steady state, thus this increased exposure at early cycles is not expected to provide any safety concerns.

The reason for lower clearance patients in Central/Eastern Europe is not known and could be a chance finding. Further, the venetoclax dose is titrated up for 5 weeks and a table for dose modifications due to toxicity is provided in section 4.2 of the SmPC. Thus, it does not appear that any changes in posology for patients in Central/Eastern Europe are warranted.

Only one dosing regimen was used in study GO28667 and thus, the usefulness of the exposureefficacy analysis is limited. Shrinkage from the popPK was relatively high (31-54%) indicating difficulty for the model to estimate individual parameters, further limiting the value of the exposure-efficacy analysis.

As expected, the exposure-response analysis showed no significant relationships with venetoclax exposure.

The information from the exposure-response analyses are of limited value but the venetoclax dosing regimen in combination with rituximab can be supported based on the clinical efficacy data (see Clinical Efficacy section).

Only one dosing regimen was used in study GO28667. For the exposure-safety analyses, data from study M13-365 was also included.  While the data from M13-365 was for only around 50 patients, the usefulness of exposure-safety analyses could have been higher than for the exposure-efficacy since several doses were studied in M13-365. For subjects who did not have evaluable PK data and were not included in the population PK analysis, the primary PK parameters were imputed using the population estimates and the individual subject's covariate values. Since data from M13-365 was not included in the popPK model, the exposures for patients in M13-365 is not adequately described by the applicants approach.  In addition, high shrinkage from the popPK model is still an issue further limiting the usefulness of the exposure-safety analysis.

The exposure safety/tolerability parameters showed no statistically significant or clinically meaningful relationships with venetoclax exposure. While the exposure-safety has several limitations it suggested that no statistically significant improvement in the safety profile would be expected with lower venetoclax exposure over the tested venetoclax dose range. This would suggest that the approved 400 mg dosing regimen of venetoclaxm which was chosen for study GO28667 was appropriate from an exposure-safety standpoint. (see also Clinical Safety section).

The usefulness of the conducted exposure-efficacy and exposure-safety modeling analyses are limited but using the approved doses of venetoclax and rituximab appear appropriate. This is supported by the pharmacokinetics, no clinically relevant DDI between venetoclax and rituximab was found in the observed data or in the popPK analysis.

## 2.3.6. Conclusions on clinical pharmacology

Clinical pharmacology aspects have been adequately studied. No relevant changes are needed in section 5.2 in the SmPC.

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

## Study M13-365 A Phase 1b Study Evaluating the Safety and Tolerability of Venetoclax (ABT199) in Combination with Rituximab in Subjects with Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.

First subject study visit 25 July 2012, ongoing, data cut off 01 July 2016.

The primary objectives of this study were to assess the safety profile, determine the maximum tolerated dose (MTD), and establish the Recommended Phase 2 Dose (RPTD) of venetoclax when administered in combination with rituximab in subjects with relapsed chronic lymphocytic leukemia (CLL).

Ramp up dosing of venetoclax was modified to 20 mg, 50 mg, 100 mg, 200 mg (or additional lead-in steps to designated cohort dose). After a week at the designated cohort dose of venetoclax, the combination of venetoclax and rituximab was started.

Up to 50 subjects with relapsed CLL or SLL were planned. As of the data cutoff for this interim CSR, 49 subjects have been treated with at least 1 dose of venetoclax and are included in the safety population, including 8 subjects in the expanded safety cohort.

For the combination period, rituximab was administered monthly on Day 1 of Months 1 to 6 for an overall duration of approximately 6 months. After discontinuation of rituximab, subjects were allowed to receive venetoclax monotherapy for up to 4 years following the date of the last subject enrolled.

## Efficacy Results:

All efficacy analyses were exploratory. The 49 subjects enrolled in the study were included across 5 dose-escalating cohorts, in addition to 1 safety expansion cohort at the RPTD and schedule. The efficacy results are summarized as follows: Overall, the majority of subjects (42 [85.7%]) achieved investigator assessed objective response, 25/49 (51.0%) subjects achieved CR or CRi.

## Safety Results:

Analysis of overall safety in Study M13-365 at doses from 200 to 600 mg venetoclax did not convincingly demonstrate a relationship between dose and safety. Incidences of treatment emergent adverse events in the Blood and Lymphatic Disorders, Gastrointestinal Disorders, General Disorders and Administration Site Conditions, Metabolism and Nutrition Disorders, Skin and Subcutaneous Tissue Disorders, Musculoskeletal and Connective Tissue Disorders, and Investigations SOCs and grade 3 or 4 adverse events overall were numerically lowest in the 400 mg dose group compared to total subjects. The selection of 400 mg as the dose to explore further in the safety expansion portion of this study (Cohort 6) was based on the balance of safety and efficacy data.

## 2.4.2. Main study(ies)

## Study MURANO

<div style=\"page-break-after: always\"></div>

## Methods

This is a multicentre, Phase III, open-label, randomized study in relapsed/refractory patients with chronic lymphocytic leukemia to evaluate the benefit of venetoclax plus rituximab compared with bendamustine plus rituximab.

## Study participants

## Main inclusion criteri a:

- CLL (Hallek et al 2008)
- Relapsed disease: Achieved CR/PR but evidence of progression after 6 months or more.
- Refractory disease: Treatment failure or progression within 6 months or less after last leukaemia therapy.
- At least one, but no more than three lines of therapy. At least one prior standard chemotherapy regimen according to guidelines.
- Prior bendamustine only if DOR &gt; 24 months.
- ECOG 1 or less.
- Adequate bone marrow, renal and hepatic function.

## Main exclusion criteria :

- Transformation to aggressive lymphoma (Richter, DLBCL, pro-lymphocyte), CNS involvement.
- Prior allogenic SCTP
- Intolerance etc. to bendamustine, rituximab
- Autoimmune haemolysis, ITP
- Positive tests for HIV, hepatitis B/C
- Cardiovascular instability grade 3 or more.

## Treatments

Experimental therapy: Venetoclax 400 mg daily p.o. (after ramp-up over 4-5 weeks according to SPC and to avoid tumour lysis)  for up to two years + rituximab 375 mg/m2 cycle 1 and 500 mg/m2 cycles 2-6 (SPC), cycle length 28 days.

Control therapy : Bendamustin 70 mg/m2 day 1 and 2 for 6 cycles and rituximab 375 mg/m2 cycle 1 and 500 mg/m2 cycles 2-6 (SPC), cycle length 28 days.

<div style=\"page-break-after: always\"></div>

## Objectives

## Outcomes/endpoints

Primary endpoint : PFS (in EU investigator assessed, in US IRC)

Secondary endpoints : CR (IRC), ORR (IRC), OS, MRD, and subgroup by 17 p status PFS, CR, (IRC), ORR (IRC), MRD.

Exploratory endpoints: Relationship between Bcl-2 expression and outcome, 'other' biomarkers and outcome.

PRO: Treatment-related symptoms by M.D. symptom inventory (MDASi), EORTC QLQ-C30 and module CLL16. Change from baseline QKQ-C30. Interference of disease symptoms and treatment related symptoms on QoL with MDASI.

Stratification 17 p status, risk status, geographic region, stratified log rank (non-stratified log rank for 'confirmation) .

- Risk status: High risk (17p del, no response to first line therapy, relapse within 12 month after chemotherapy, 24 month after chemo-immuno-therapy). Low risk: complementary set.
- Region: US/Canada, Australia/New/Zealand, Western Europe, Central/Eastern Europe, Asia, Latin America.
- Planned sample size 370 individuals randomized 1:1. Final analysis at 186 investigator assessed PFS events, one interim analysis at 140 events, i.e. 38% of events in the long run (assuming no cure, relative survival).

## Sample size

The  primary  endpoint  of  PFS  was  used  to  determine  the  sample  size  for  the  study  based  on  the following assumptions: Two-sided log-rank test at the 0.05 level of significance, 80% power to detect a hazard ratio (HR) for venetoclax + R versus BR of 0.66, corresponding to an approximate median improvement  of  15.2  months  to  23  months  (34%  reduction  in  risk  of  a  PFS  event),  Exponential distribution  of  PFS,  an  annual  dropout  rate  of  5%,  One  interim  analysis  (IA)  for  efficacy  at approximately  75%  of  total  investigator-  assessed  PFS  events  (approximately  140  investigatorassessed PFS events). With these assumptions, 186 investigator-assessed PFS events were required to achieve 80% power for the primary analysis of PFS in all patients. It is planned to enroll 370 patients across  the  two  arms  with  1:1  randomization  ratio.  Sample  size  calculations  were  performed  with Insightful S+ Seq Trial S 2.0.6.

## Randomisation

Block stratified randomization procedure using an interactive voice/web based system was used.

## Blinding (masking)

The study was open label.

<div style=\"page-break-after: always\"></div>

## Statistical methods

Analysis  sets. The  primary  analysis  of  efficacy  was  based  on  the  set  of  all  randomized  patients  (cf intention-to-treat  population).  The  primary  analysis  of  safety  was  based  on  the  set  of  all  treated patients, who received at least one dose of the study treatment.

Planned interim analysis . One IA was planned during the conduct of the study to assess the efficacy of V+R combination  treatment  compared  with  B+R  treatment,  and  to  allow  for  release  of  the  results earlier  than  the  planned  final  analysis  in  case  of  significant  differences.  The  IA  is  performed  when approximately 140 investigator-assessed PFS events have occurred in both treatment arms combined (75% of  the  186  events  required  for  the  final  primary  efficacy  analysis  is  available).  The  stopping boundary follows a unified family with parameter P=2 (Kittelson and Emerson 1999). Based on 140 events, the duration of PFS will be tested at the IA, which corresponds to approximately a 2-sided pvalue of 2 * 0.0013 = 0.0026.

Primary  efficacy  endpoint  analysis. A  two-sided  stratified  (by  17p  deletion  status,  risk  status  and geographic region) log-rank test adjusted for interim analysis; a two sided unstratified log-rank test was performed to confirm the primary analysis. Median PFS and 95% confidence limits were estimated using Kaplan-Meier methodology.

The primary endpoint will be tested at the IA with 140 events, which corresponds to approximately a 2-sided p-value of 2 * 0.0013 = 0.0026. In case the observed number of events is not exactly 140, the boundaries will be updated to reflect the number of events based on investigator assessment and IRC assessment, respectively.

Secondary  efficacy  endpoint  analysis. To  adjust  for  multiple  testing  of  the  key  secondary  efficacy endpoints, a fixed sequence hierarchical testing procedure was used for specific key efficacy endpoints. Formal  statistical  testing  of  response  rates  between  the  two  arms  was  performed  at  the  two-sided significance  level  of  0.05  using  a  stratified  Cochran-Mantel-Haenszel  (CMH)  test.  Time-to-event endpoints such as OS, EFS, and TTNT were analyzed using the same statistical methods described for the primary analysis of PFS. Additional secondary endpoints were not tested formally.

Secondary endpoints were tested following a multiple testing procedure based on hierarchical testing. To adjust for multiple testing of key secondary efficacy endpoints, a fixed sequence testing procedure was used (Westfall and Krishen 2001). The following endpoints were tested in the following order: 1) IRC-assessed CR rate, 2) IRC-assessed best ORR, 3) OS.

If  the study meets its primary efficacy endpoint of prolonged PFS in the treatment arm (V+R) in all randomized patients, then a formal statistical test of IRC-assessed CR rate between the two arms will be performed at the two-sided significance level of 0.05 by using a stratified Cochran-Mantel-Haenszel (CMH) test with stratification factors. If the study does not meet its primary endpoint, then this test will not be performed. The IRC-assessed best ORR will only be tested by the same stratified CMH test once the null hypothesis for IRC-assessed CR rate in all randomized patients has been rejected at a two-sided significance level of 0.05.

If the null hypothesis for IRC-assessed best ORR has been rejected at a two-sided significance level of 0.05, the duration of OS will be analyzed at a nominal alpha spend of 0.0001. Approximately 3 years after the last patient is enrolled, OS will be tested at a two-sided significance level of 0.0499.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

Figure 3: Participant flow in Murano study

<!-- image -->

BR = bendamustine; V+ R = Venetoclax and rituximab;

<div style=\"page-break-after: always\"></div>

## Recruitment

Study period : February 2014 (first patient screened) to May 2017 (cut-off for interim analysis)

Study centres: 20 countries (14 EU), 109 centres.

## Conduct of the study

A total of 59.9% (233/389) of patients (67.0% [130/194] in the VR arm and 52.8% [103/195] in the BR arm) had at least one major protocol deviation reported. The most common deviations (reported for 66.0% of patients in the VR arm and 50.3% of patients in the BR arm) were procedural deviations, the majority of which were missing individual laboratory assessments at a single response assessment.

None of the major deviations were likely to have an impact on study outcomes.

## Baseline data

The median age was 65 years, and about 14% were older than 75, i.e. rather typical for CLL studies with moderately intensive therapies. As expected there was a dominance of males, about 3/4. About half were considered 'high risk' and close to 20% had del 17p. About 1/3 enrolled in Western Europe and 1/3 in Central and Eastern Europe.

<div style=\"page-break-after: always\"></div>

Table 2: Disease Characteristics

|                                            |                                            | BR        | VR        |
|--------------------------------------------|--------------------------------------------|-----------|-----------|
| Time from diagnosis, median, years         | Time from diagnosis, median, years         | 7         | 6         |
| ECOG                                       | 0                                          | 56%       | 57%       |
| Fludarabine refractory, yes                | Fludarabine refractory, yes                | 16%       | 14%       |
| Bulky disease, lgl largest diameter ≥10 cm | Bulky disease, lgl largest diameter ≥10 cm | 15%       | 13%       |
| Lymphocytes                                | ≥100 10 9 /l                               | 28%       | 26%       |
| B-symptoms                                 | Fever yes Night sweats yes Weight loss yes | 2% 21% 7% | 2% 22% 6% |
| Del 17 p                                   | yes Local lab Central lab                  | 21% 27%   | 18% 27%   |
| Del 11 q                                   | yes                                        | 27%       | 27%       |
| Trisomy 12                                 | yes                                        | 19%       | 13%       |
| Del 13 q                                   | yes                                        | 76%       | 83%       |
| Risk status                                | High*                                      | 61%       | 56%       |
| IgVH unmutated                             | IgVH unmutated                             | 68%       | 68%       |
| TP53 mutated                               | TP53 mutated                               | 28%       | 25%       |
| Beta 2 micro > 3.5 mg/l                    | Beta 2 micro > 3.5 mg/l                    | 68%       | 66%       |

Fludarabine refractory: no response or progression on therapy or within 6 months.

High risk: 17p del, no response to first line therapy, relapse within 12 month after chemotherapy, 24 month after chemoimmuno-therapy.

FCR: Fludarabine, Cyclophosphamide, Rituximab

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

## Table 3: Summary (investigator assessment)

<!-- image -->

| Parameter                                                                 | Bendamustine plus Rituximab (N-195)     | Venetoclax plus Rituximab (N-194)   |
|---------------------------------------------------------------------------|-----------------------------------------|-------------------------------------|
| Progression-Free Survival                                                 |                                         |                                     |
| Patients with event                                                       | 114 (58.5%)                             | 32 (16.5%)                          |
| Time to Event (months)                                                    |                                         |                                     |
| Median [95% CI]                                                           | 17.0 [15.5, 21.6]                       | NE                                  |
| P-value (log-rank test, stratified)                                       | p<0.0001                                | p<0.0001                            |
| Hazard Ratio (stratified). [95% Cl]                                       | 0.17 [0.11, 0.25]                       | 0.17 [0.11, 0.25]                   |
| Estimate of 1-year PFS rate [95% Cl]                                      | 72.5% [66.0, 79.1]                      | 92.7% [89.1, 96.4]                  |
| Estimate of 2-year PFS rate [95% Cl]                                      | 36.396 [28.5, 44.0]                     | 84.9% [79.1, 90.8]                  |
| PFS in 17p del populationt                                                | n=46                                    | n=46                                |
| Patients with event                                                       | 27 (58.7%6)                             | 7 (15.296)                          |
| Time to Event (months)                                                    |                                         |                                     |
| Median [95% C1]                                                           | 15.4 [10.0, 21.0]                       | NE [27.6, NE]                       |
| P-value (log-rank test, unstratified)                                     | p<0.0001*                               | p<0.0001*                           |
| Hazard Ratio (unstratified), [95% Cl]                                     | 0.13 [0.05, 0.31]                       | 95.6% [89.5, 100]                   |
| Estimate of 1-year PFS rate [95% Cl] Estimate of 2-year PFS rate [95% Cl] | 64.4%6 [49.4, 79.4] 27.8%6 [11.1, 44.4] | 81.5% [66.9, 96.1]                  |
| Overall Response                                                          |                                         |                                     |
| Responders                                                                | 132 (67.7%)                             | 181 (93.396)                        |
| 95% C1                                                                    | [60.6, 74.2]                            | [88.8, 96.4]                        |
| Difference in Response Rates [95% Cl]                                     | 25.6% [17.9, 33.3]                      |                                     |
| P-value (CMH test) CR                                                     | 15 (7.7%)                               | p<0.0001* 47 (24.296)               |
| Cri                                                                       | 1 (0.5%6)                               | 5 (2.6%)                            |
| nPR                                                                       | 12 (6.2%)                               | 6 (3.196)                           |
|                                                                           |                                         | 123 (63.4%)                         |
| PR Nonresponders                                                          | 104 (53.396) 63 (32.3%)                 | 13 (6.796)                          |
| Stable disease Progressive disease                                        | 44 (22.6%) 6 (3.1%)                     | 4 (2.196) 3 (1.5%)                  |
| Missing or unevaluable Complete Response Rate                             | 13 (6.7%)                               | 6 (3.1%)                            |
| Complete Responders                                                       | 18 (8.2%)                               | 52 (26.896)                         |
| 959 C1                                                                    | [4.8, 13.0]                             | [20.7, 33.6]                        |
| Difference in Response Rates [95% Cl]                                     | 18.6% [11.0, 26.2]                      | 18.6% [11.0, 26.2]                  |
|                                                                           |                                         | 15 (7.7%6)                          |
| Time to event (months)                                                    |                                         |                                     |
| P-value (CMH test)                                                        | p<0.0001*                               | p<0.0001*                           |
| Overall Survival                                                          |                                         |                                     |
| Patients with event                                                       | 27 (13.8%)                              |                                     |
| Median [95% Cl]                                                           | NE                                      | NE                                  |
| Estimate of 1-year 0S rate [95% Cl]                                       | 91.1% [86.9, 95.3]                      | 95.9%6 [93.0, 98.7]                 |
| Estimate of 2-year OS rate [95% Cl]                                       | 86.6%6 [81.4, 91.7]                     | 91.9% [87.7. 96.1]                  |
| Best MRD-negativity Rate in peripheral blood*                             |                                         |                                     |
| MRD Negative, n (%)                                                       | 45 (23.1%)                              | 162 (83.5%)                         |
| MRD Positive, n (%)                                                       | 150 (76.9%)                             | 32 (16.5%6)                         |
| 95% CI for MRD negative rates Difference in MRD negative rates [95% Cl]   | [17.4, 29.6]                            | [77.5, 88.4]                        |
| P-value (Chi-square test)                                                 | p < 0.0001*                             | 60.4% [52.3, 68.8]                  |

<div style=\"page-break-after: always\"></div>

Table 4:  Investigator-assessed progression-free survival in patients with previously treated CLL in MURANO (data cut-off date 8 May 2017)

|                                                                  | Venetoclax + rituximab N = 194                                   | Bendamustine + rituximab N = 195                                 |
|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
| Number of events (%)                                             | 32 (16.5)                                                        | 114 (58.5)                                                       |
| Disease progression                                              | 21                                                               | 98                                                               |
| Death events                                                     | 11                                                               | 16                                                               |
| Median, months (95% CI)                                          | NR                                                               | 17.0 (15.5, 21.6)                                                |
| Hazard ratio (95% CI)                                            | 0.17 (0.11, 0.25)                                                | 0.17 (0.11, 0.25)                                                |
| P-value a                                                        | <0.0001                                                          | <0.0001                                                          |
| 12-month PFS estimate (95% CI)                                   | 92.7 (89.1, 96.4)                                                | 72.5 (65.9, 79.1)                                                |
| 24-month PFS estimate (95% CI)                                   | 84.9 (79.1, 90.6)                                                | 36.3 (28.5, 44.0)                                                |
| CI = confidence interval; NR = not reached a Stratified P-value. | CI = confidence interval; NR = not reached a Stratified P-value. | CI = confidence interval; NR = not reached a Stratified P-value. |

At an updated efficacy analysis with all patients off treatment (data cut-off date 8 May 2018 and median follow-up of 36 months) the 36-month PFS estimate in the venetoclax + rituximab arm was 71.4% [95% CI: 64.8, 78.1] and in the bendamustine + rituximab arm was 15.2% [95% CI: 9.1, 21].

Figure 4: Kaplan-Meier curves of investigator-assessed progression-free survival (intent-totreat population) in MURANO (data cut-off date 8 May 2018)

<!-- image -->

In total, 130 patients in the venetoclax + rituximab arm completed 2 years of venetoclax treatment without progression. Of the 130 patients, 92 patients completed the 6-month post treatment follow-up visit. The estimated PFS rate at 6 months post treatment was 92%.

<div style=\"page-break-after: always\"></div>

At 6 months, the VR arm had 8 PFS events compared with 14 PFS events in the BR arm. Also, the BR arm had 18 patients censored within the first six months compared with only one patient censored in the VR arm. Per medical monitor review, the 18 patients censored in the BR arm included 14 who dropped out from the study early and 4 patients who did not have adequate response assessment beyond 6 months.

Table 5: Summary of Sensitivity Analyses for PFS (by Investigator and IRC Assessments, ITT Population)

|                                     | Investigator-Assessed PFs   | Investigator-Assessed PFs   | IRC-AssessedPFS   | IRC-AssessedPFS   |
|-------------------------------------|-----------------------------|-----------------------------|-------------------|-------------------|
| Analysis                            | BR N=195                    | V+R N=194                   | BR N=195          | V+R N=194         |
| Unstratifiedlog-ranktest            |                             |                             |                   |                   |
| Patients with event                 | 114                         | 32                          | 106               | 35                |
| Median PFS [95% CI], m0             | 17.0 [15.5, 21.6]           | NE                          | 18.1 [15.8, 22.3] | NE                |
| HR (versus BR) [95% CI]             | 0.17 [0.12, 0.26]           | 0.17 [0.12, 0.26]           | 0.20 [0.14, 0.30] | 0.20 [0.14, 0.30] |
| p-value (log-rank test)             | <0.0001                     | <0.0001                     | <0.0001           | <0.0001           |
| Censoring forNonProtocol Therapy\"   |                             |                             |                   |                   |
| Patients with event                 | 110                         | 31                          | 101               | 34                |
| Median PFS [95% CI], m0             | 17.1 [15.7, 21.6]           | NE                          | 19.0 [16.2, 22.5] | NE                |
| HR (versus BR) [95% CI]             | 0.17 [0.11, 0.25]           | 0.17 [0.11, 0.25]           | 0.19 [0.13, 0.29] | 0.19 [0.13, 0.29] |
| p-value (log-rank test)             | <0.0001                     | <0.0001                     | <0.0001           | <0.0001           |
| CensoringformissingPFs assessmentsb |                             |                             |                   |                   |
| Patient with event                  | 106                         | 30                          | 96                | 35                |
| Median PFS [95% CI], m0             | 18.0 [15.7, 22.3]           | NE                          | 19.6 [16.2, 22.8] | NE                |
| HR (versus BR) [95% CI]             | 0.16 [0.11, 0.25]           | 0.16 [0.11, 0.25]           | 0.20 [0.13, 0.30] | 0.20 [0.13, 0.30] |
| p-value (log-rank test)             | <0.0001                     | <0.0001                     | <0.0001           | <0.0001           |

BR=bendamustine plus rituximab; Cl=confidence interval; HR=hazard ratio; INV=investigator; IRC=Independent Review Committee; mo=months; NPT=non-protocol therapy; PFS=progression-free survival; V+R=venetoclax plus rituximab.

- Patients who started non-protocol specified anti-CLL treatment before occurrence of PFS event were censored at the time of the new treatment initiation. Two of the 194 patients (1.0%) in the V+R arm and 8/195 patients (4.1%) in the BR arm received new anti-leukemic treatments before progression

Patients with PD or death reported after missing more than one visit consecutively were censored at their last adequate response assessment date before the missed visits.

Efficacy results for the pre-specified primary analysis (data cut-off date 8 May 2017) were also assessed by an Independent Review Committee (IRC) demonstrating a statistically significant 81% reduction in the risk of progression or death for patients treated with venetoclax + rituximab (hazard ratio: 0.19 [95% CI: 0.13, 0.28]; P&lt;0.0001). Additional efficacy results for the pre-specified primary analysis are shown below:

<div style=\"page-break-after: always\"></div>

Table 6: Efficacy results in MURANO - Secondary endpoints

|                                                       | Investigator assessed               | Investigator assessed               | IRC assessed                        | IRC assessed                        |
|-------------------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| Endpoint                                              | Venetoclax + rituximab N = 194      | Bendamustine + rituximab N = 195    | Venetoclax + rituximab N = 194      | Bendamustine + rituximab N = 195    |
| Response rate                                         |                                     |                                     |                                     |                                     |
| ORR, %(95% CI)                                        | 93.3 (88.8, 96.4)                   | 67.7 (60.6, 74.2)                   | 92.3 (87.6, 95.6)                   | 72.3 (65.5, 78.5)                   |
| CR+CRi, (%)                                           | 26.8                                | 8.2                                 | 8.2                                 | 3.6                                 |
| nPR, (%)                                              | 3.1                                 | 6.2                                 | 1.5                                 | 0.5                                 |
| PR, (%)                                               | 63.4                                | 53.3                                | 82.5 a                              | 68.2 a                              |
| MRD negativity rate at end of combination treatment b |                                     |                                     |                                     |                                     |
| Peripheral blood, %(95% CI) c                         | 62.4 (55.2, 69.2)                   | 13.3 (8.9, 18.9)                    | NA                                  | NA                                  |
| Bone marrow, %(95% CI) d                              | 15.5(10.7, 21.3)                    | 1.0 (0.1, 3.7)                      | NA                                  | NA                                  |
| Overall Survival e                                    |                                     |                                     |                                     |                                     |
| Number of events (%)                                  | 15 (7.7)                            | 27 (13.8)                           |                                     |                                     |
| Hazard ratio (95% CI)                                 | 0.48 (0.25, 0.90)                   | 0.48 (0.25, 0.90)                   |                                     |                                     |
| Time to next anti-leukaemic therapy                   | Time to next anti-leukaemic therapy | Time to next anti-leukaemic therapy | Time to next anti-leukaemic therapy | Time to next anti-leukaemic therapy |
| Number of events (%)                                  | 23 (11.9)                           | 83 (42.6)                           | NA                                  | NA                                  |
| Median, months (95% CI)                               | NR                                  | 26.4                                | NA                                  | NA                                  |
| Hazard ratio                                          | 0.19 (0.12, 0.31)                   | 0.19 (0.12, 0.31)                   | NA                                  | NA                                  |

CR = complete remission; CRi = complete remission with incomplete marrow recovery; IRC = independent review committee; MRD = minimal residual disease; nPR = nodular partial remission; NA = not available; NR = not reached; ORR = overall response rate (CR + CRi + nPR + PR); PR = partial remission.

a The discrepancy between IRC- and investigator-assessed CR rate was due to interpretation of residual adenopathy on CT scans. Eighteen patients in the venetoclax + rituximab arm and 3 patients in the bendamustine + rituximab arm had negative bone marrow and lymph nodes &lt;2 cm.

b Minimal residual disease was evaluated using allele-specific oligonucleotide polymerase chain reaction (ASO-PCR) and/or flow cytometry. The cut-off for a negative status was one CLL cell per 10 4 leukocytes.

c Of those with MRD assay results available in peripheral blood, 72.5% (121/167) in the venetoclax + rituximab arm and 20% (26/128) in the bendamustine + rituximab arm were found to be MRD negative.

d Of those with MRD assay results available in bone marrow, 76.9% (30/39) in the venetoclax + rituximab arm and 6.7% (2/30) in the bendamustine + rituximab arm were found to be MRD negative. e Overall survival data are not yet mature.

Median DOR was not reached with median follow up of approximately 23.8 months.

<div style=\"page-break-after: always\"></div>

Figure 5: Kaplan-Meier curves of overall survival (intent-to-treat population) in MURANO (data cut-off date 8 May 2017)

<!-- image -->

## Results of subgroup analyses

The observed PFS benefit of venetoclax + rituximab  compared with bendamustine + rituximab was consistently observed across all subgroups of patients evaluated, including age (&lt; 65, ≥ 65 years and &lt; 75, ≥ 75 years), prior lines of therapy (1, &gt;1), bulky disease (&lt; 5 cm, ≥ 5 cm), 17p deletion, 11q deletion, TP53 mutation , IgVH mutation, and refractory versus relapse to most recent therapy.

<div style=\"page-break-after: always\"></div>

Figure 6: Forest plot of Investigator-Assessed PFS in Subgroups from MURANO

|                                                       |                                                       | Bendamustine+ Rituximab (N=195)   | Bendamustine+ Rituximab (N=195)   | Venetoclax+ Rituximab (N=194)   | Venetoclax+ Rituximab (N=194)   |              |              |                              |                                |
|-------------------------------------------------------|-------------------------------------------------------|-----------------------------------|-----------------------------------|---------------------------------|---------------------------------|--------------|--------------|------------------------------|--------------------------------|
| Subgroups                                             | Total n                                               | n                                 | Median (Months)                   | n                               | Median (Months)                 | Hazard Ratio | 95%Wald CI   | Venetoclax+ Rituximab better | Bendamustine+ Rituximab better |
| All Patients                                          | 389                                                   | 195                               | 17.0                              | 194                             | NE                              | 0.17         | (0.12, 0.26) |                              |                                |
| Chromosome17pDeletion(central)                        |                                                       |                                   |                                   |                                 |                                 |              |              |                              |                                |
| Nomal                                                 | 250                                                   | 123                               | 21.4                              | 127                             | NE                              | 0.19         | (0.12,0.32)  |                              |                                |
| Abnormal                                              | 92                                                    | 46                                | 15.4                              | 46                              | NE                              | 0.13         | (0.05, 0.29) |                              |                                |
| p53Mutation                                           |                                                       |                                   |                                   |                                 |                                 |              |              |                              |                                |
| Unmutated                                             | 277                                                   | 133                               | 21.2                              | 144                             | NE                              | 0.15         | (0.09,0.25)  |                              |                                |
| Mutated                                               | 99                                                    | 51                                | 12.9                              | 48                              | NE                              | 0.19         | (0.10, 0.36) |                              |                                |
| Age Group 65(yr)                                      |                                                       |                                   |                                   |                                 |                                 |              |              |                              |                                |
| 65                                                    | 186                                                   | 89                                | 15.4                              | 97                              | NE                              | 0.11         | (0.06, 0.21) |                              |                                |
| >=65                                                  | 203                                                   | 106                               | 21.7                              | 97                              | NE                              | 0.24         | (0.14, 0.41) | HIH                          |                                |
| Age Group75(yr)                                       |                                                       |                                   |                                   |                                 |                                 |              |              |                              |                                |
| <75                                                   | 336                                                   | 171                               | 16.4                              | 165                             | NE                              | 0.17         | (0.11, 0.26) |                              |                                |
| >=75                                                  | 53                                                    | 24                                | 22.9                              | 29                              | NE                              | 0.23         | (0.08,0.64)  |                              |                                |
| NumberofPriorRegimens                                 |                                                       |                                   |                                   |                                 |                                 |              |              |                              |                                |
| 1                                                     | 228                                                   | 117                               | 16.6                              | 111                             | NE                              | 0.14         | (0.08,0.24)  |                              |                                |
| >1                                                    | 161                                                   | 78                                | 17.0                              | 83                              | NE                              | 0.24         | (0.13,0.42)  | 工I工                          |                                |
| Bulky Disease (Lymph Nodes with the Largest Diameter) | Bulky Disease (Lymph Nodes with the Largest Diameter) |                                   |                                   |                                 |                                 |              |              |                              |                                |
| 5cm                                                   | 197                                                   | 97                                | 17.0                              | 100                             | NE                              | 0.13         | (0.07,0.24)  |                              |                                |
| >=5cm                                                 | 172                                                   | 88                                | 15.7                              | 84                              | NE                              | 0.24         | (0.14,0.40)  |                              |                                |
| BaselineIgVH MutationStatus                           |                                                       |                                   |                                   |                                 |                                 |              |              |                              |                                |
| Mutated                                               | 104                                                   | 51                                | 22.9                              | 53                              | NE                              | 0.11         | (0.04,0.31)  |                              |                                |
| Unmutated                                             | 246                                                   | 123                               | 15.7                              | 123                             | NE                              | 0.16         | (0.10, 0.26) |                              |                                |
| Refractoryvs.RelapsetoMostRecentPriorTherapy          |                                                       |                                   |                                   |                                 |                                 |              |              |                              |                                |
| Refractory                                            | 59                                                    | 29                                | 13.6                              | 30                              | NE                              | 0.32         | (0.15, 0.70) |                              |                                |
| Relapse                                               | 330                                                   | 166                               | 18.6                              | 164                             | NE                              | 0.14         | (0.09, 0.23) |                              |                                |

17p deletion status was determined based on central laboratory test results.

Unstratified hazard  ratio is displayed on the X-axis with logarithmic scale. NE=not evaluable.

## Ancillary analyses

## Figure 7: Kaplan-Meier Plot of Investigator-Assessed Progression-Free Survival by 17p Deletion Status (ITT Population)

Venetoclax Interim Analysis - Based on Data as of Clinical Data Cutoff Date: 08MAY2017

<!-- image -->

Patient 17p deletion status was determined based on central laboratory test results.

<div style=\"page-break-after: always\"></div>

Figure 8: Kaplan-Meier Plot of Time to New Anti-CLL Treatment (ITT Population)

<!-- image -->

Time (month)

Table 7: Time to New Anti-CLL Treatment (ITT Population) (data cut-off date 8 May 2017)

<!-- image -->

|                                                                                                                  | Bendamustine+Rituximab (N=195)   | Venetoclax+Rituximab (N=194)   |
|------------------------------------------------------------------------------------------------------------------|----------------------------------|--------------------------------|
| Patients with event (8) Earliest contributing event New anti-leukemic treatment Death Patients without event (8) | 83( (42.68) 61 22 112 (57.4)     | 23 (11.98) 10 13 171 (88.1#)   |
| Time to Event (Month) Median 958 CI 25% and 75g-ile                                                              | 26.4 (21.9, 33.1) 13.8, 33.1     | NE NE                          |
| Hazard Ratio 958 CI Time Point Analysis 1 Year Duration Patients remaining at risk                               |                                  | 0.19 (0.12, 0.31)              |
| Event Free Rate () 1056                                                                                          |                                  |                                |
| Patients remaining at risk Event Free Rate () 958 CI                                                             | 0.0* to 33.8*                    | NE 0.3* to 37.4*               |
| Stratified Analysis p-value (log-rank)                                                                           |                                  |                                |
| Range                                                                                                            |                                  |                                |
| Hazard Ratio                                                                                                     |                                  | 0.19                           |
| 958 CI                                                                                                           |                                  | (0.12, 0.31)                   |
| Unstratified Analysis p-value (log-rank)                                                                         |                                  | <.0001                         |
|                                                                                                                  | 138                              | 179                            |
|                                                                                                                  | 77.90                            | 94.80                          |
|                                                                                                                  | (71.84,83.95)                    | (91.67,97.94)                  |
| 2 Year Duration                                                                                                  | 44 52.09                         | 98 90.00                       |
|                                                                                                                  | (43.96,60.23)                    | (85.56,94.44)                  |

<div style=\"page-break-after: always\"></div>

## Minimal Residual Disease

Peripheral blood MRD response was assessed using iwCLL recommended ASO-PCR and flow cytometry for all patients and across serial timepoints. MRD was considered negative if the result was less than one CLL cell in 10000 leukocytes (MRD value &lt;0.0001, 10-4).

For both ASO-PCR and flow cytometry methods, only samples that had a limit of detection (LOD) below 10-4 were considered for MRD determination. In addition, for flow cytometry, samples were required to have a minimum of 200,000 leukocytes assessed, which adhered to the prior reporting conventions for MRD flow cytometry data in clinical trials.

Unlike peripheral blood MRD assessments that were performed serially throughout the study, MRD assessments in bone marrow were only required for responders (CR or PR) at the end of combination treatment response visit or at any other point during the study that a patient became a responder. A total of 115/389 patients [29.6%] had post baseline BM samples available for MRD assessment (74/194 patients [38.1%] in the VR arm and 41/195 patients [21.0%] in the BR arm).

Comparison of MRD-negativity between the two arms in peripheral blood at the end of the combination treatment response (EOCTR) visit was a secondary endpoint for this study.

Table 8: MRD-Negativity (Peripheral Blood) at the End of Combination Treatment Visit - ITT Population (data cut-off date 8 May 2017)

| Visit                                                               | Bendamustine+Rituximab (N=195)   | Venetoclax+Rituximab (N=194)   |
|---------------------------------------------------------------------|----------------------------------|--------------------------------|
| End Of Combination Treatment Response Visit                         |                                  |                                |
| MRD Negative MRD Positive                                           | 26 (13.3) 169( 86.78)            | 121(62.4) 73( 37.6%)           |
| 958 CI for MRD negative rates                                       | (8.90, 18.92)                    | (55.15, 69.21)                 |
| Difference in MRD negative rates 95: CI p-value (Chi-square)        | (40.44,57.64)                    |                                |
| Odds Ratio 958 CI MRD Assay Positive                                | 102 ( 52.38)                     | 46 ( 23.78)                    |
| MRD Undetermined                                                    | 2 1.0)                           | 2( 1.0)                        |
| PD or death before visit                                            | 23 ( 11.88)                      | 9 [ 4.6%)                      |
| Withdrew from study before visit due to to reasons other than death | 15( 7.78)                        | 4( 2.1)                        |
| MRD Missing                                                         | 27(13.8)                         | 12(6.2)                        |

958 CI for rates were constructed using Pearson-Clopper method. 95s CI for difference in rates were constructed using Anderson-Hauck method.

The MRD-negativity rate in peripheral blood among investigator-assessed complete responders (CR/CRi) was 94.2% (49/52 patients) in the VR arm compared with 31.3% (5/16 patients) in the BR arm; and among investigator-assessed partial responders (nPR/PR) was 86.0% (111/129 patients) in the VR arm compared with 32.8% (38/116 patients) in the BR arm.

Concordance between the MRD status in peripheral blood and in bone marrow was 84.3% based on 108 pairs of post-baseline samples across both arms; 48 out of 60 (80.0%) patients that had been

<div style=\"page-break-after: always\"></div>

measured as MRD negative by blood also measured MRD negative in bone marrow samples while 48 out of 53 (90.6%) patients that measured MRD negative in bone marrow also measured negative in blood.

## Subgroup Analyses of Investigator Assessed PFS

Table 9: Subgroup Analysis of PFS By stratification factors (data cut-off date 8 May 2017)

|                          |         | Bendamustine+ Rituximab (N=195)   | Bendamustine+ Rituximab (N=195)   | Venetoclax+ Rituximab (N=194)   | Venetoclax+ Rituximab (N=194)   |              |                         | Venetoclax+      | Bendamustine-    |
|--------------------------|---------|-----------------------------------|-----------------------------------|---------------------------------|---------------------------------|--------------|-------------------------|------------------|------------------|
| Randomization Strata     | Total n | n                                 | Median (Months)                   | n                               | Median (Months)                 | Hazard Ratio | 95%Wald CI              | Rituximab better | Rituximab better |
| All Patients             | 389     | 195                               | 17.0                              | 194                             | NE                              | 0.17         | (0.12.0.26)             |                  |                  |
| 17p Deletion (IvRS)      |         |                                   |                                   |                                 |                                 |              |                         |                  |                  |
| NUrNl Abnormal           | 313 76  | 155 40                            | 19.6 122                          | 158 36                          | NE NE                           | 0.18 0.14    | (0.12.0.28) (0.06.0.33) |                  |                  |
| Risk Stalus (huRS)       |         |                                   |                                   |                                 |                                 |              |                         |                  |                  |
| Low                      | 178     | 88                                | 21.6                              | 90                              | NE                              | 0.14         | (0.07.0.28)             |                  |                  |
| High                     | 211     | 107                               | 15.4                              | 104                             | NE                              | 0.19         | (0.11,0.30)             |                  |                  |
| GeographicRegion (lvRS)  |         |                                   |                                   |                                 |                                 |              |                         |                  |                  |
| United States/Canada     |         | 18                                | 15.8                              | 16                              |                                 | 0.29         | (0.10.0.83)             |                  |                  |
| Australa/New Zealand     | 9       | 42                                |                                   | 44                              |                                 | 0.34         |                         |                  |                  |
| Westem Curope            | 121     | 65                                | 1761                              |                                 |                                 | 0.11         | (0.05.0.22)             |                  |                  |
| Cental and Eastem Europe | 130     | 66                                | 15.5                              | 83                              |                                 | 0.13         | (0.06.0.27)             |                  |                  |
| Asia                     | 8       | 4                                 | 13.6                              | 4                               | EEHEE                           | 0.28         | (0.03,2.69)             |                  |                  |

Table 10: Subgroup analysis By demographics (data cut-off date 8 May 2017)

|                          |          | Bendamustine+ Rituximab (N=195)   | Bendamustine+ Rituximab (N=195)   | Venetoclax+ Rituximab (N=194)   | Venetoclax+ Rituximab (N=194)   |              |                           | Venetoclax+     | Bendamustine+   |
|--------------------------|----------|-----------------------------------|-----------------------------------|---------------------------------|---------------------------------|--------------|---------------------------|-----------------|-----------------|
| DemographicSubgroups     | Total ni | n                                 | Median (Months)                   | n                               | Median (Monlhs)                 | Hazard Ratio | 95% Wald CI               | Rtuximab beller | Ritrmab belter  |
| All Patiente             | 389      | 105                               | 17.0                              | 194                             | NE                              | 0.17         | (0.12. 0.26)              |                 |                 |
| AgeGroup65(yn) 65 =65    | 186 203  | 89 106                            | 15.4 21.7                         |                                 | NE                              | 0.11 0.24    | (0.06.021) (0.14, 0.41)   |                 |                 |
| Age Group 75 (yr) 75 =75 | 336      | 171 24                            | 16.4 22.9                         | 165 29                          | NE                              | 0.17 0.23    | (0.11, 0.26) (0.08, 0.64) |                 |                 |
| Sex Male Female          | 82       |                                   | 16.4 17.3                         |                                 | NE                              | 0.19 0.12    | (0.12. 0.30) (62.0*500)   |                 |                 |
| Race While Non-White     | 359 12   | 178 6                             | 17.1 16.3                         | 181 6                           | NE                              | 0.18 0.24    | (0.12.0.27) (0.02, 2.30)  |                 |                 |

<div style=\"page-break-after: always\"></div>

Table 11: Subgroup analysis by prognosis (data cut-off date 8 May 2017)

|                                                              |         | Bendamustinet Rituximab (N=195)   | Bendamustinet Rituximab (N=195)   | Venctoclax+ Rituximab (N=194)   | Venctoclax+ Rituximab (N=194)   |              |                           | Venetoclax+    | Bendamustine+    |
|--------------------------------------------------------------|---------|-----------------------------------|-----------------------------------|---------------------------------|---------------------------------|--------------|---------------------------|----------------|------------------|
| Blomarker                                                    | Total n | n                                 | Median (Months)                   | n                               | Median (Months)                 | Hazard Ratlo | 95% Wald D                | Rinimab better | Ritiximah better |
| All Patients                                                 | 389     | 195                               | 17.0                              | 194                             | NE                              | 0.17         | (0.12, 0.26)              |                |                  |
| Chromosome 17p Deletion (cenlral) Normal Abnomal             | 2       | 12                                | 1.4                               | 126                             | N                               | 8.13         | 1812: 031                 |                |                  |
| Chromosome 1lq Deletlon Normal Abnomal                       | 217 125 | 105 64                            | 21.7 15.7                         | 112 61                          | NE                              | 0.22 0.11    | (0.13. 0.37) (0.05, 0.25) | HH             |                  |
| p53 Mutation Unmutated Mulaled                               | 277 99  | 133 51                            | 21.2 12.9                         | 144 48                          | NE                              | 0.15 0.19    | (0.09, 0.25) (0.10, 0.36) |                |                  |
| Baseline IoVH Mutation Status Mutaled Unmutated              | 144     |                                   | .9                                |                                 |                                 | 0.11         | (0.04.0.31)               |                |                  |
| Baseline Beta-2 Microglobulin =35mg/l                        | 123     | 59                                |                                   |                                 | N                               | 0.16         | (0.10, 0.26)              |                |                  |
| >3.5mgL                                                      | 252     | 127                               | 16.3 18.7                         |                                 | NE NE                           | 0.07 0.25    | (0.03.0.18) (0.16, 0.39)  |                |                  |
| p53 Mutation and/or 17p Delelion (central) Unmutated Mutaled |         |                                   |                                   |                                 |                                 | 0.16         | (0.08,0.29)               |                |                  |
|                                                              | 201 147 |                                   |                                   | 106 72                          | NE                              | 0.17         | (0.10, 0.31)              |                |                  |

Table 12: Subgroup analysis by prognosis, update May 2018

|                                            |         | Bendamustine+ Rituximab (N=195)   | Bendamustine+ Rituximab (N=195)   | Venetoclax+ Rituximab (N=194)   | Venetoclax+ Rituximab (N=194)   |              |              | Venetoclax+      | Bendamustinet    |
|--------------------------------------------|---------|-----------------------------------|-----------------------------------|---------------------------------|---------------------------------|--------------|--------------|------------------|------------------|
| Biomarker                                  | Total n | n                                 | Median (Months)                   | n                               | Median (Months)                 | Hazard Ratio | 95%Wald CI   | Rituximab better | Rituximab better |
| All Patients                               | 389     | 195                               | 17.0                              | 194                             | NE                              | 0.19         | (0.14, 0.27) |                  |                  |
| Chromosome 17pDeletion(central)            |         |                                   |                                   |                                 |                                 |              |              |                  |                  |
| Nomal                                      | 250     | 123                               | 21.4                              | 127                             |                                 | 0.19         | (0.13.0.29)  |                  |                  |
| Abnormal                                   | 92      | 46                                | 15.4                              | 45                              | NE                              | 0.21         | (0.11,0.39)  |                  |                  |
| Chromosome 11qDeletion                     |         |                                   |                                   |                                 |                                 |              |              |                  |                  |
| Normal                                     | 217     | 105                               | 22.1                              | 112                             | 44.3                            | 0.26         | (0.17, 0.39) | HH               |                  |
| Abnormal                                   | 125     | 64                                | 15.7                              | 61                              | NE                              | 0.11         | (0.05. 0.21) | IH               |                  |
| p53Mutation                                |         |                                   |                                   |                                 |                                 |              |              |                  |                  |
| Unmutated                                  | 276     | 132                               | 21.2                              | 144                             | NE                              | 0.16         | (0.10,0.24)  |                  |                  |
| Mutated                                    | 99      | 51                                | 12.9                              | 48                              | 0'9F                            | 0.25         | (0.15, 0.43) |                  |                  |
| BaselinelgVH MutationStatus                |         |                                   |                                   |                                 |                                 |              |              |                  |                  |
| Mutated                                    | 104     | 51                                | 34.2                              |                                 | NE                              | 0.16         | (0.07,0.33)  |                  |                  |
| Unmutated                                  | 246     | 123                               | 15.7                              |                                 | 44.3                            | 0.16         | (0.11, 0.24) |                  |                  |
| Baseline Beta-2Microglobulin               |         |                                   |                                   |                                 |                                 |              |              |                  |                  |
| =3.5mgL                                    | 123     | 59                                | 16.3                              | 64                              | NE                              | 0.13         | (0.07, 0.24) | 工H               |                  |
| > 3.5 mg/L                                 | 252     | 127                               | 19.5                              | 125                             | 44.3                            | 0.25         | (0.17, 0.36) |                  |                  |
| p53 Mutation andlor 17p Deletion (central) |         |                                   |                                   |                                 |                                 |              |              |                  |                  |
| Unmutated                                  | 201     | 95                                | 22.8                              | 105                             | NE                              | 0.16         | (0.10, 0.27) |                  |                  |
| Mutated                                    | 147     | 75                                | 14.6                              | 72                              | NE                              | 0.23         | (0.15, 0.37) |                  |                  |

<div style=\"page-break-after: always\"></div>

Table 13: Subgroup analysis by disease characteristics (data cut-off date 8 May 2017)

<!-- image -->

|                                               |                               | Bendamustine+ 95   | Bendamustine+ 95   |       |        |       |              |    | Bendamustine -   |
|-----------------------------------------------|-------------------------------|--------------------|--------------------|-------|--------|-------|--------------|----|------------------|
| BaselineCharacteristics                       | Total n                       | n                  | MondRs             | n     | Moedes | Ratio | PPeM %S6     | pe |                  |
| AllPatients                                   | 389                           | 195                | 17.0               | 194   | NE     | 0.17  | (0.12,0.26)  |    |                  |
| RenalImpairment Status Normai Moderate        |                               |                    |                    | 驿     |        | 8:33  |              |    |                  |
| HepaticInpairmentStatus ormal Moderate Severe | 2                             | 14                 |                    | 148   |        |       |              |    |                  |
| Rai Stage                                     |                               | 99629              | 3288               | 34933 |        | 68883 |              |    |                  |
| 5550m                                         | 5550m                         | 28                 | 15.9               | 184   | NE     | 8:24  | (8:94: 8:46) |    |                  |
| >=10cm                                        | >=10cm                        |                    | 13.1               | 13    | NE     | 8.18  | (8:87: 8:33  |    |                  |
| NumberofPriorRegimens 768 143                 | NumberofPriorRegimens 768 143 |                    | 188191             |       | NE     | 8:34  | (8:98 8:383  |    |                  |

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 14: Summary of main study, primary analyses of May 2018

| Title: Study GO28667: A multicenter, Phase III, open-label, randomized study in relapsed/refractory patients with chronic lymphocytic leukemia to evaluate the benefit of venetoclax (GDC-0199/ABT-199) plus rituximab compared with bendamustine plus rituximab   | Title: Study GO28667: A multicenter, Phase III, open-label, randomized study in relapsed/refractory patients with chronic lymphocytic leukemia to evaluate the benefit of venetoclax (GDC-0199/ABT-199) plus rituximab compared with bendamustine plus rituximab   | Title: Study GO28667: A multicenter, Phase III, open-label, randomized study in relapsed/refractory patients with chronic lymphocytic leukemia to evaluate the benefit of venetoclax (GDC-0199/ABT-199) plus rituximab compared with bendamustine plus rituximab   | Title: Study GO28667: A multicenter, Phase III, open-label, randomized study in relapsed/refractory patients with chronic lymphocytic leukemia to evaluate the benefit of venetoclax (GDC-0199/ABT-199) plus rituximab compared with bendamustine plus rituximab   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                   | EudraCT 2013-002110-12                                                                                                                                                                                                                                             | EudraCT 2013-002110-12                                                                                                                                                                                                                                             | EudraCT 2013-002110-12                                                                                                                                                                                                                                             |
| Design                                                                                                                                                                                                                                                             | ongoing, open-label, international, multicenter, randomized, comparative Phase III study                                                                                                                                                                           | ongoing, open-label, international, multicenter, randomized, comparative Phase III study                                                                                                                                                                           | ongoing, open-label, international, multicenter, randomized, comparative Phase III study                                                                                                                                                                           |
| Design                                                                                                                                                                                                                                                             | Duration of main phase: Duration of Run-in phase:                                                                                                                                                                                                                  | Duration of main phase: Duration of Run-in phase:                                                                                                                                                                                                                  | First Patient Screened: 26 Feb 2014 Last Patient Randomized: 23 Sep 2015 Data cut-off: 08 May 2017 Ramp up of venetoclax for 5 weeks prior                                                                                                                         |
| Design                                                                                                                                                                                                                                                             | Duration of                                                                                                                                                                                                                                                        | Extension phase:                                                                                                                                                                                                                                                   | to rituximab add-on not applicable                                                                                                                                                                                                                                 |
| Hypothesis                                                                                                                                                                                                                                                         | Superiority                                                                                                                                                                                                                                                        | Superiority                                                                                                                                                                                                                                                        | Superiority                                                                                                                                                                                                                                                        |
| Treatments groups                                                                                                                                                                                                                                                  | V+R                                                                                                                                                                                                                                                                | V+R                                                                                                                                                                                                                                                                | Venetoclax+Rituximab followed by venetoclax monotherapy until PD or max 2 years, 194 patients                                                                                                                                                                      |
| Treatments groups                                                                                                                                                                                                                                                  | B+R                                                                                                                                                                                                                                                                | B+R                                                                                                                                                                                                                                                                | Bendamustin+Rituximab. for six cycles (or PD), 195 patientsx                                                                                                                                                                                                       |
| Endpoints and definitions                                                                                                                                                                                                                                          | Primary endpoint                                                                                                                                                                                                                                                   | INV-PFS                                                                                                                                                                                                                                                            | Progression-free survival                                                                                                                                                                                                                                          |
| Endpoints and definitions                                                                                                                                                                                                                                          | Secondary endpoints (with MTP):                                                                                                                                                                                                                                    | 1) IRC-CR 2) IRC-ORR 3) OS                                                                                                                                                                                                                                         | 1) IRC-assessed complete response rate 2) IRC-assessed best objective response rate 3) overall survival                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                                                                                          | Exploratory endpoints (without MTP):                                                                                                                                                                                                                               | see CSR                                                                                                                                                                                                                                                            | see CSR                                                                                                                                                                                                                                                            |
| Database lock                                                                                                                                                                                                                                                      | 2017-09-09                                                                                                                                                                                                                                                         | 2017-09-09                                                                                                                                                                                                                                                         | 2017-09-09                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| Analysis description                            | Primary Analysis                                                                                                                                                                                                     | Primary Analysis                                                                                                                                                                                                     | Primary Analysis                                                                                                                                                                                                     |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis population and time point description  | ITT First Patient Screened: 26 Feb 2014 Last Patient Randomized: 23 Sep 2015 Data cut-off: 08 May 2017                                                                                                               | ITT First Patient Screened: 26 Feb 2014 Last Patient Randomized: 23 Sep 2015 Data cut-off: 08 May 2017                                                                                                               | ITT First Patient Screened: 26 Feb 2014 Last Patient Randomized: 23 Sep 2015 Data cut-off: 08 May 2017                                                                                                               |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                      | B+R                                                                                                                                                                                                                  | V+R                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                   | 195                                                                                                                                                                                                                  | 194                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability | PRIMARY: INV-PFS, (Median, stratified)                                                                                                                                                                               | 17                                                                                                                                                                                                                   | Not estimated                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | CI95%                                                                                                                                                                                                                | [15.5, 21.6]                                                                                                                                                                                                         | Not estimated                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | SECONDARY: IRC-CC                                                                                                                                                                                                    | 7 (3.6%)                                                                                                                                                                                                             | 16 (8.2%)                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability | CI95%                                                                                                                                                                                                                | [1.5%, 7.3%]                                                                                                                                                                                                         | [4.8%, 13.1%]                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | SECONDARY: IRC-ORR                                                                                                                                                                                                   | 141 (72.3%)                                                                                                                                                                                                          | 179 (92.3%)                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability | CI95%                                                                                                                                                                                                                | [65.5%, 78.5%]                                                                                                                                                                                                       | [87.6%, 95.6%]                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | SECONDARY: OS                                                                                                                                                                                                        | Not estimated                                                                                                                                                                                                        | Not estimated                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | CI95%                                                                                                                                                                                                                | Not estimated                                                                                                                                                                                                        | Not estimated                                                                                                                                                                                                        |
| Effect estimate per comparison                  | PRIMARY: INV-PFS                                                                                                                                                                                                     | Comparison groups                                                                                                                                                                                                    | V+R:B+R                                                                                                                                                                                                              |
| Effect estimate per comparison                  | PRIMARY: INV-PFS                                                                                                                                                                                                     | Hazard Ratio, stratified                                                                                                                                                                                             | 0.17                                                                                                                                                                                                                 |
| Effect estimate per comparison                  | PRIMARY: INV-PFS                                                                                                                                                                                                     | CI95%                                                                                                                                                                                                                | [0.11, 0.25]                                                                                                                                                                                                         |
| Effect estimate per comparison                  | PRIMARY: INV-PFS                                                                                                                                                                                                     | P-value                                                                                                                                                                                                              | <0.0001                                                                                                                                                                                                              |
| Effect estimate per comparison                  | SECONDARY: IRC-CC                                                                                                                                                                                                    | Comparison groups                                                                                                                                                                                                    | V+R:B+R                                                                                                                                                                                                              |
| Effect estimate per comparison                  | SECONDARY: IRC-CC                                                                                                                                                                                                    | Difference in Response Rates of Complete Response (IRC)                                                                                                                                                              | 4.7%                                                                                                                                                                                                                 |
| Effect estimate per comparison                  | SECONDARY: IRC-CC                                                                                                                                                                                                    | CI95%                                                                                                                                                                                                                | [-0.3%, 9.6%]                                                                                                                                                                                                        |
| Effect estimate per comparison                  | SECONDARY: IRC-CC                                                                                                                                                                                                    | P-value                                                                                                                                                                                                              | 0.0814                                                                                                                                                                                                               |
| Effect estimate per comparison                  | SECONDARY: IRC-ORR                                                                                                                                                                                                   | Comparison groups                                                                                                                                                                                                    | V+R:B+R                                                                                                                                                                                                              |
| Effect estimate per comparison                  | SECONDARY: IRC-ORR                                                                                                                                                                                                   | Difference in Response Rates of Objective Response Rates (ORR)                                                                                                                                                       | 20.0%                                                                                                                                                                                                                |
| Effect estimate per comparison                  | SECONDARY: IRC-ORR                                                                                                                                                                                                   | CI95%                                                                                                                                                                                                                | [12.4%, 27.56%]                                                                                                                                                                                                      |
| Effect estimate per comparison                  | SECONDARY: IRC-ORR                                                                                                                                                                                                   | P-value                                                                                                                                                                                                              | < 0.0001                                                                                                                                                                                                             |
| Effect estimate per comparison                  | SECONDARY: IRC-OS                                                                                                                                                                                                    | Comparison groups                                                                                                                                                                                                    | V+R:B+R                                                                                                                                                                                                              |
| Effect estimate per comparison                  | SECONDARY: IRC-OS                                                                                                                                                                                                    | Hazard Ratio                                                                                                                                                                                                         | Not estimated                                                                                                                                                                                                        |
| Effect estimate per comparison                  | SECONDARY: IRC-OS                                                                                                                                                                                                    | CI95%                                                                                                                                                                                                                | Not estimated                                                                                                                                                                                                        |
| Effect estimate per comparison                  | SECONDARY: IRC-OS                                                                                                                                                                                                    | P-value                                                                                                                                                                                                              | Not estimated                                                                                                                                                                                                        |
| Notes                                           | The results show superiority of V+R over B+R regarding the primary endpoint in terms of statistical significance and clinical relevance. The secondary endpoints are not-significant, but descriptive statistics are | The results show superiority of V+R over B+R regarding the primary endpoint in terms of statistical significance and clinical relevance. The secondary endpoints are not-significant, but descriptive statistics are | The results show superiority of V+R over B+R regarding the primary endpoint in terms of statistical significance and clinical relevance. The secondary endpoints are not-significant, but descriptive statistics are |

<div style=\"page-break-after: always\"></div>

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

A randomised (1:1), multicenter, open-label phase III study evaluated the efficacy and safety of Venclyxto + rituximab versus BR in patients with previously treated CLL. Patients in the Venclyxto + rituximab arm completed the Venclyxto 5-week dose-titration schedule and then received 400 mg once daily for 24 months from Cycle 1 Day 1 of rituximab in the absence of disease progression or unacceptable toxicity. Rituximab was initiated after the 5-week dose-titration schedule at 375 mg/m 2 for Cycle 1 and 500 mg/m 2  for Cycles 2-6. Each cycle was 28 days. Patients randomised to BR received bendamustine at 70 mg/m 2  on Days 1 and 2 for 6 cycles and rituximab as described above.

The overall study design was accepted by the SAWP/CHMP: Bendamustin + rituximab versus venetoclax + rituximab for six cycles followed by monotherapy with venetoclax until PD with PFS as primary endpoint - highlighting that the benefit of continuing ABT-199 until progression without a placebo control will not only lead to results that are non-interpretable as regards the benefit of ABT199 'maintenance' treatment, but also to events of progression on-therapy of ABT-199, in contrast to the reference arm where most progression events will occur off-therapy. Also, the MAH was advised to avoid cross-over until informative survival data are available.

Changes/deviations from advice/planned design were: Venetoclax was to be administered for a total of 6 + 18 months not until PD. An interim analysis was undertaken at about 35% of events of PFS in the long run (assuming no cure). The difference between events of progression on and off therapy was not addressed.

A follow-up advice was requested and important and accepted changes included an interim analysis to be conducted 'if the number of investigator assessed events of PFS is less than 160 as of 12 months after the enrolment of the last patient. Further time to progression was changed to total duration of therapy 12 months. The possibility of cross-over at time of progression was no longer optional.

Median age was 65 years (range: 22 to 85); 74% were male, and 97% were white. Median time since diagnosis was 6.7 years (range: 0.3 to 29.5). Median prior lines of therapy was 1 (range: 1 to 5); and included alkylating agents (94%), anti-CD20 antibodies (77%), B-cell receptor pathway inhibitors (2%) and prior purine analogs (81%, including 55% FCR). At baseline, 46.6% of patients had one or more nodes ≥5 cm, and 67.6% had ALC ≥25 x 10 9 /l. A 17p deletion was detected in 26.9% of patients, TP53 mutations in 26.3%, 11q deletion in 36.5%, and unmutated IgVH gene in 68.3%. Median follow-up time for primary analysis was 23.8 months (range: 0.0 to 37.4 months).

Enrolled patients with at least one prior adequate treatment regimen (according to clinical guidelines) represent a rather heterogeneous population: median (and mean) time from diagnosis was about 7 years, but the majority of patients had been treated with only one prior regimen. It should be noticed, however, that diagnosis does not imply need for therapy. On the other hand, more than 50% of patients were considered 'high risk' and non-adjusted beta 2 microglobulin was above 3.5 mg/dl in close to 70% of patients. Subgroup analysis in terms of PFS, indicate no important relationship between prognosis and HR for PFS, but data may be misleading due to the low event rate in the VR arm.

Progression-free survival (PFS) was assessed by investigators using the International Workshop for Chronic Lymphocytic Leukaemia (IWCLL) updated National Cancer Institute-sponsored Working Group (NCI-WG) guidelines (2008).

<div style=\"page-break-after: always\"></div>

## Efficacy data and additional analyses

Efficacy results for PFS at the time of pre-specified primary interim analysis (data cut-off date 8 May 2017) showed an event rate of  16.5% of the VR combination as compared to 58.5% of the BR combination, with an improvement of the PFS  of HR 0.17 (0.11, 0.25). At an updated efficacy analysis with all patients off treatment (data cut-off date 8 May 2018 and median follow-up of 36 months) the 36-month PFS estimate in the venetoclax + rituximab arm was 71.4% [95% CI: 64.8, 78.1] and in the bendamustine + rituximab arm was 15.2% [95% CI: 9.1, 21].

Efficacy results for the pre-specified primary analysis (data cut-off date 8 May 2017) were also assessed by an Independent Review Committee (IRC) demonstrating a statistically significant 81% reduction in the risk of progression or death for patients treated with venetoclax + rituximab (hazard ratio: 0.19 [95% CI: 0.13, 0.28]; P&lt;0.0001). Median DOR was not reached with median follow up of approximately 23.8 months.

In total, 130 patients in the venetoclax + rituximab arm completed 2 years of venetoclax treatment without progression. Of the 130 patients, 92 patients completed the 6-month post treatment follow-up visit. The estimated PFS rate at 6 months post treatment was 92%.

The observed PFS benefit of venetoclax + rituximab  compared with bendamustine + rituximab was consistently observed across all subgroups of patients evaluated, including age (&lt; 65, ≥ 65 years and &lt; 75, ≥ 75 years), prior lines of therapy (1, &gt;1), bulky disease (&lt; 5 cm, ≥ 5 cm), 17p deletion, 11q deletion, TP53 mutation , IgVH mutation, and refractory versus relapse to most recent therapy.

In terms of response rate (IRC by convention, no confirmation required, RECIST 1.1), CR rate is borderline 8% vs. 4% (p=0.08). Of note, in the investigator analysis, CR rates are much higher 27% vs. 8% (p&lt;0.0008). This discrepancy was most likely due to the assessment of borderline lymph nodes. MRD negativity at end of dual therapy also favoured the venetoclax arm. According to the analysis plan, ORR should be assessed only if CR is positive: ORR 92% vs. 72% (p&lt;0.0001). MRD data may be used to bridge between the validity of IRC and investigator assessment of CR .

Formally PFS (primary endpoint) was highly significant and convincing, HR 0.17 (p&lt; 0.0001). The event rate in the venetoclax arm was only 17%. Furthermore there were two steps in the PFS curves: in the BR arm at about 6 months and in the VT arm at about 2 years, i.e. at time of stopping therapy. In the control arm, PFS is likely to be sufficiently stable, event rate 58% and long follow-up off therapy. The pattern of recurrence in the venetoclax arm is not possible to estimate.

In the updated cutoff of May 2018, altogether 61 patients provided PFS data at 36 months, 12 months after stopping venetoclax. Based on the shapes of the time to event curves it appears possible to conclude that the event rate with respect to progressive disease is not worse, if not better, in the VR arm after end of venetoclax than in the BR arm after month 24.

As a concequence, it also appears possible to conclude that 'truncated' time without therapy is longer than 18 months (24 - 6 months), meaning that time without therapy when data become mure mature is highly likely to be longer in the VT arm compared with the BT arm. At the updated analysis, a total of 61 randomized patients had died; 22/194 patients (11.3%) in the V+R arm and 39/195 patients (20.0%) in the BR arm with an exploratory HR of 0.5 (0.3; 0.85).

Section 5.1 of the SmPC has been revised to include information on the results of the MURANO trial.

The recommended dose of venetoclax in combination with rituximab is 400 mg once daily. Rituximab should be adminstered after the patient has completed the dose-titration schedule and has received

<div style=\"page-break-after: always\"></div>

the recommended daily dose of 400 mg venetoclax for 7 days. Venetoclax should be taken for 24 months from Cycle 1 Day 1 of rituximab. Section 4.2 of the SmPC has been updated with relevant posology information on the combination with rituximab.

## 2.4.4. Conclusions on the clinical efficacy

In overall the efficacy of venetoclax in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy has been demonstrated.

The CHMP considers the following measures necessary to address issues related to efficacy:

- Submission of the final CSR of the MURANO study including updated efficacy data.

## 2.5. Clinical safety

## Introduction

The safety profile of Venclyxto, as reflected in the current SPC, is based on pooled, single-arm data of 296 patients with treatment experienced CLL treated with venetoclax 400 mg monotherapy once daily.

The most serious adverse reaction was tumour lysis syndrome (TLS). The most commonly occurring adverse reactions (≥20%) of any grade in patients receiving Venclyxto monotherapy were neutropenia/neutrophil count decreased, diarrhoea, nausea, anaemia, upper respiratory tract infection, fatigue, hyperphosphataemia, vomiting, and constipation. The most frequently reported serious adverse reactions (≥2%) were pneumonia, febrile neutropenia, and TLS.

Based on this experience, AEs of special interest included:

<div style=\"page-break-after: always\"></div>

Table 15: AEs of special interest - search criteria

| Selected TEAEs                                                                                                                                                                                                                                                                                                                                                                                                                                           | Search Criteria                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Tumor Lysis Syndrome (AE)                                                                                                                                                                                                                                                                                                                                                                                                                                | SMQ - 'Tumor Lysis Syndrome' (narrow) *                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Grade ≥ 3 neutropenia                                                                                                                                                                                                                                                                                                                                                                                                                                    | PT terms - \"neutropenia\", \"neutrophil count decreased\", \"febrile neutropenia\", \"agranulocytosis\", \"neutropenic infection\", and \"neutropenic sepsis\"                                                                                                                                                                                                                                                                                                      |
| Infection Serious infection Grade ≥ 3 infection                                                                                                                                                                                                                                                                                                                                                                                                          | SOC of \"Infections and Infestations\"                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Second primary malignancy                                                                                                                                                                                                                                                                                                                                                                                                                                | SMQ - \"malignant tumours\" (narrow) and \"myelodysplastic syndromes\" (narrow)                                                                                                                                                                                                                                                                                                                                                                              |
| Drug-Induced Liver Injury (AE)                                                                                                                                                                                                                                                                                                                                                                                                                           | PT Term - 'drug-induced liver injury'                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Grade ≥ 3 thrombocytopenia                                                                                                                                                                                                                                                                                                                                                                                                                               | PT terms - \"thrombocytopenia\" and \"platelet count decreased\"                                                                                                                                                                                                                                                                                                                                                                                             |
| Grade > 3 infusion-related reaction                                                                                                                                                                                                                                                                                                                                                                                                                      | Roche standard AEGT - 'Infusion-related reaction + hypersensitivity'                                                                                                                                                                                                                                                                                                                                                                                     |
| * Additionally, the assessment of Howard criteria were used to identify laboratory abnormalities consistent with tumour lysis syndrome. This broad search method ensured that all relevant cases were identified using adverse events and/or laboratory data. AE = adverse events; AEGT = adverse event group term; CRF = case report form; MedDRA = Medical Dictionary for Regulatory Activities; PT = preferred term; SMQ = Standardized MedDRA Query; | * Additionally, the assessment of Howard criteria were used to identify laboratory abnormalities consistent with tumour lysis syndrome. This broad search method ensured that all relevant cases were identified using adverse events and/or laboratory data. AE = adverse events; AEGT = adverse event group term; CRF = case report form; MedDRA = Medical Dictionary for Regulatory Activities; PT = preferred term; SMQ = Standardized MedDRA Query; |

In addition events of Richter transformation were closely monitored (RMP: important potential risk).

Table 16: Laboratory Abnormalities Search Criteria

| Laboratory Abnormalities                                                                                                                                                                  | Search Criteria                                                                                                                                                                                                                                                                   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Tumor Lysis Syndrome (Howard Criteria;                                                                                                                                                    | ≥ 2 of the following metabolic abnormalities within 24 hours of each other (applicable to post-dose laboratory values only): • Uric Acid > 476 μmol/L or 8.0 mg/dL • Potassium > 6.0 mmol/L • Inorganic Phosphorus > 1.5 mmol/L or 4.5 mg/dL • Calcium < 1.75 mmol/L or 7.0 mg/dL |
| Potential Drug-Induced Liver Injury (Hy's Law)                                                                                                                                            | Post-dose laboratory ALT or AST > 3 × ULN in combination with total bilirubin > 2 × ULN that occur within 72 hours of each other                                                                                                                                                  |
| ALT = alanine aminotransferase; AST = aspartate aminotransferase; L = litre; μmol = micromole; mg/dL = milligram/deciliter; mmol = millimole; mEq = milliequivalent; ULN = upper limit of | ALT = alanine aminotransferase; AST = aspartate aminotransferase; L = litre; μmol = micromole; mg/dL = milligram/deciliter; mmol = millimole; mEq = milliequivalent; ULN = upper limit of                                                                                         |

<div style=\"page-break-after: always\"></div>

## Patient exposure

## Table 17: Venetoclax exposure

<!-- image -->

As of the 8 May 2017 clinical cut-off date for Study GO28667, patients received a median of 6 cycles of bendamustine (range:  0-6). Overall, 70/188 of patients (37.2%) had a bendamustine dose modification due to AEs (62 patients [33.0%]) and/or other reason (12 patients [6.4%]). A total of 26/188 patients (13.8%) in the BR arm experienced 36 AEs that led to reduction of the bendamustine dose.

<div style=\"page-break-after: always\"></div>

Table 18: Extent of Exposure to Treatment during the VR Combination Treatment Period and Venetoclax Single Agent Treatment Period (Safety Population) (data cut-off date 8 May 2017)

<!-- image -->

after thelast Rituximab exposure. Treatment duration is defined as the total number of days with Venetoclax exposure within each total target dose within each period.

<div style=\"page-break-after: always\"></div>

## Adverse events

## Table 19: Overview of adverse events

|                                                              | BendamustinetRituximah..Jenetoclax (400 mgl +Rituximab (N=188)   | (N=210]      |
|--------------------------------------------------------------|------------------------------------------------------------------|--------------|
| Total mumber of patients with at least one AE                | 185(98.4%)                                                       | 210(100.0%)  |
| Total mmber of AEs                                           | 1830                                                             | 2541         |
| Total number of deaths                                       | 27(14.49)                                                        | 16......     |
| Total number ( of patients withdraw from study dhe to an 1AE | 11.0.5%)                                                         | 0            |
| Total number of patients with at least one                   |                                                                  |              |
| AE with fatal outcome                                        | 11J..5...9%)                                                     | 11 5.291     |
| Serious HE                                                   | 81(43.1号)                                                        | 98 1.46.761  |
| Serious AE  leading to withdrawal from any treatment         | 12 1.6.45)                                                       | 17 8.141     |
| Serioug AE leading to withdrawal from Venetoclax             | 0                                                                | 16 ...7..61  |
| Serious AE leading to dose interruption                      | 19 (10.1)                                                        | 49 L.23.361  |
| Serious AE leading to dose reduction                         | 111.5.96)                                                        | 7 (3.3%]     |
| Related Serious AE                                           | 51(27.1%)                                                        | 45 J.21.411  |
| AE leading  to withdrawal fram any treatent                  | 18 1..9..6%)                                                     | 33 715.741   |
| AE leading to withdrawal fram Venetoclax                     | 0                                                                | 27 1.12.961  |
| AE leading to dose interruption                              | 76(40.46)                                                        | 144 J.68.661 |
| AE leading to dose reduction                                 | 28(14.9%)                                                        | 34 11.16.24) |
| Related AE                                                   | 170(90.4%)                                                       | 185188..14)  |
| Related AE leading to withdrawal from any tmeatment          | 15 1.8.0%)                                                       | 21 ( 10.0%)  |
| Related AE leading to withdrawal from Venetoclax             | 0                                                                | 17....8..11  |
| Related AE leading to dose interruption                      | 65(34.66)                                                        | 1241.59.061  |
| Related PE_leading to dose reduction                         | 26 (13.86)                                                       | 311.14.8%1   |
| Grade 3,4 AE (at greatest intensity)                         | 125 (66.56)                                                      | 159775.761   |

Overall, the most frequently reported body systems (SOCs ≥ 10%) with AEs considered related to venetoclax by the investigator included Blood and Lymphatic System Disorders (61.0%), Gastrointestinal Disorders (38.6%), Infections and Infestations (24.8%), General Disorders and Administration Site Conditions (17.6%), Metabolism and Nutrition Disorders (17.1%), and Investigations (15.7%).

<div style=\"page-break-after: always\"></div>

Table 20: Overview of Adverse Events during VR Combination Treatment Period and Venetoclax Single Agent Treatment Period (data cut-off date 8 May 2017)

<!-- image -->

|                                                            | V+R. Combination Regimen                          | V+R. Combination Regimen                         |
|------------------------------------------------------------|---------------------------------------------------|--------------------------------------------------|
|                                                            | Venetoclax+R Combination Treatment Feriod (N=194) | Venetoclan Single Hgent Treatment Period (N=171) |
| Total nmber of patients with at least one AE               | 192 (99.08)                                       | 143 (83.6)                                       |
| Total number of AEs                                        | 1673                                              | 589                                              |
| Total number of deaths                                     | 11 (5.74)                                         | 4 (2.3)                                          |
| Total number of patients withdrawn from study due to an AE | 0                                                 | 0                                                |
| Total number of patients with at least one                 |                                                   |                                                  |
| AE with fatal outcome                                      | 8 (4.18]                                          | 2 (1.24)                                         |
| Barioug AE                                                 | 63 (32.51]                                        | 36 (21.18)                                       |
| Serious AE leading to withdrawal from any treatment        | 9 (4.68]                                          | 6 (3.58)                                         |
| Serious AE leading to withdrawal from Venetoclax           | 8 4.1)                                            | 6 (3.51)                                         |
| Serious AE leading to dose reduction                       | 5 (2.68]                                          | 0                                                |
| Berious AE leading to dose interruption                    | 34 (17.51)                                        | 14 8.24)                                         |
| Related Borious AE                                         | 34 (17.58)                                        | 12 7.081                                         |
| AE leading to withdrawal from any treatment                | 17 8.841                                          | 13 7.611                                         |
| E Teading to withdraval from Venetoelaw                    | 13 6.78]                                          | 12 7.08)                                         |
| HE leading to dose reduction                               | 24 (12.48)                                        | 2.941                                            |
| AE leading to dose interruption                            | 125 (+*+9)                                        | 47 (27.58)                                       |
| Related AE                                                 | 165 (85.18)                                       | 68 (39.8*)                                       |
| Related AE 2 leading to withdrawal from any treatment      | 10 15.21]                                         | 6 (5.38)                                         |
| Related AE leading to withdrawal from Venetoclax           | 7 (3.68)                                          | 9 5.381                                          |
| Related AE leading to dose reduction                       | 22 (11.3)                                         | 5 2.94)                                          |
| Related AE leading to dose interruption                    | 112 (57.74)                                       | 30 (17.51)                                       |
| Grade 3,4 AE (at greatest intensity)                       | 130 (67.08)                                       | 21 (12.3)                                        |

During the VR combination period, the most frequent Grade ≥3 AEs (in at least 2% of patients)  were neutropenia  [54.1%], anaemia  [8.2%], neutrophil count decreased [5.2%], pneumonia  [4.6%], thrombocytopenia [4.6%], febrile neutropenia [3.6%], tumour lysis syndrome [3.1%]), hyperglycaemia [2.1%], and autoimmune haemolytic anaemia [2.1%],

During the venetoclax single agent treatment period the most frequently reported Grade ≥ 3 AEs were neutropenia [11.1%] anaemia [2.9%], thrombocytopenia [2.3%], pneumonia [1.8%], neutrophil count decreased [1.2%], diarrhoea [1.2%], myelodysplastic syndrome [1.2%]), diabetes mellitus [1.2%] and hypertension [1.2%]. All other Grade ≥ 3 AEs were reported as unique events.

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

Table 21: Adverse Events Resulting in Death:  Safety-Evaluable Patients

| MedDRA SOC and Preferred Term                                                                       | Bendamustine+Rituximah..Venetoclax(400 mgl +Rituximab (N=188) (N=210]   |           |
|-----------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|-----------|
| Total number of deaths                                                                              | 11 (5.9%)                                                               | 11 (5.2号) |
| Infections and infestations / Pneumonia                                                             | 0                                                                       | (1.46)    |
| Blood and lymphatic system disorders / Thrombocytopenia                                             | 0                                                                       | 1(0.5%)   |
| Camdiac disorders / Cardiac failure                                                                 | 0                                                                       | 1 (0.5%)  |
| Camdiac disorders / Myocamdial infarction                                                           | 0                                                                       | 1 (0.5%)  |
| General disorders and adminigtration gite conditions / Sudden cardiac death                         |                                                                         | 1 (0.5%)  |
| Infections and infestatione / Sepsis                                                                | 2 (1.1)                                                                 | 1 (0.5%)  |
| Metabolism and nutrition disorders / Hperkalaemia                                                   | 0                                                                       | 1 (0.5%)  |
| Metabolism and mutrition disomders / Tumour lysis symdrome                                          | 0                                                                       | 1 (45'0)  |
| Neoplasms benign, maligmant and wspecified (incl cysts and polyps) / Colorectal cancer              | 0                                                                       | 1(0.5%)   |
| Nervous system disorders / Status epilepticun                                                       | 0                                                                       | 1(0.5%)   |
| Respiratory, thoracic and mediastinal disorders / Acute respiratory failure                         | 0                                                                       | 1(0.5%)   |
| MedDRA SOC and Preferred Term                                                                       | Bendamstine+Rituximah.Jeretoclax (400 mg) +Rituximsb (N=188)            | (N=210)   |
| Camiac disorders / Myocardial ischaemia                                                             | 0                                                                       | 0         |
| General disorders and administration site conditions / Sudden death                                 | 1(0.5%)                                                                 | 0         |
| Infections and infestations / Listeria sepAis                                                       | 1 (0.5%)                                                                | 0         |
| Infections and infestations / Scedospnrium infection                                                | 1(0.5%)                                                                 | 0         |
| Neoplasms benign, maligmant and wspecified (incl cysts and polyps] / Lumg neoplasm maligmant        | 2 (1.1)                                                                 | 0         |
| Neoplasmg benign, maligmant amd specified (incl cysts and polyps) / Acute myeloid leukaemia         | 1(0.5%)                                                                 | 0         |
| Necplasmg benign, maligmant and uspecified (incl cysts and polyps] / Lymphana                       | 1(0.5)                                                                  | 0         |
| Neoplasmg benign, maligmant and wspemified (incl cysts and polyps] / Maligmant neoplasm progressiom | 0                                                                       |           |
| Neoplasms benign, maligmant and wspecified (incl cysts and polyps) / Richter's symdrome             | 0                                                                       |           |
| Nervous system disorders / Haemorrhagic stroke                                                      | 1(0.5)                                                                  | 0         |
| Respiratory, thoracic and mediastinal disorders / Pulmnary embolism                                 | 1(0.5%)                                                                 | 0         |

<div style=\"page-break-after: always\"></div>

Table 22: Serious Adverse Events Occurring in ≥ 1% of Patients:  Safety-Evaluable Patient

<!-- image -->

| MedDRA System Organ Class MedDRA Preferred Term                                                                  | Bendamustine +Rituximab (N=188)   | Jeretaclax (400 mg) +Rituximab (N=210)   |
|------------------------------------------------------------------------------------------------------------------|-----------------------------------|------------------------------------------|
| Total nmber of patients with At least one adverge event                                                          | 81(43.1%)                         | 98(46.76)                                |
| Overall total nmber of events                                                                                    | 151                               | 172                                      |
| Infections and infestations                                                                                      |                                   |                                          |
| Total nunber of patients with                                                                                    |                                   |                                          |
| at least one adverse event Total number of events                                                                | 55                                | 63                                       |
| Pheumonia                                                                                                        | 15 1.8.06]                        | 16 (7.66]                                |
| Inflvenza                                                                                                        | .1.1)                             | 4 1.91                                   |
| Lung infectiom                                                                                                   |                                   | 3 J.1.481                                |
| Upper respiratory tract infectim                                                                                 | .1.18)                            | 3 (1.4%] .1.061                          |
| Pppemdieitis Cystitis                                                                                            |                                   | 2N 1.1.06]                               |
| Lower respiratory tract infectim                                                                                 | 1 J.0.58]                         | 2 (1.0%]                                 |
| Respiratory tract infection                                                                                      |                                   | 2 L.1..061                               |
| Sinusitis                                                                                                        | 1 1.0.5%]                         | 2 (1.06]                                 |
| Sepsis                                                                                                           | 4 1.2.1]                          | 1 (0.56]                                 |
| Bronchitis                                                                                                       | 2 .1.1)                           | 100                                      |
| Pharygitig                                                                                                       | 2 J.1..14)                        |                                          |
| Blood and lymphatic system disorders                                                                             |                                   |                                          |
| Total nuber of patients with                                                                                     |                                   |                                          |
| at leagt one adverse event Total number of events                                                                | 32                                | 27                                       |
| Febrile reutmpenia                                                                                               | 16 .8..58]                        | 8 (3.86]                                 |
| Autoimmune heemolytic araemia                                                                                    | 3 (1.6)                           | 4 (1.9]                                  |
| Anaemia                                                                                                          | 5 ( 2.76)                         | 3 1.41                                   |
| Neutmpenia                                                                                                       | 3 (1.6]                           | 3 (1.4%]                                 |
| Thronbocytopenia                                                                                                 | 2 1.1.15)                         | 2 (1.0%)                                 |
| Metabolism and nutrition disorders                                                                               |                                   |                                          |
| Total nuber of patients with                                                                                     |                                   |                                          |
| at least one adverse event Total number of events                                                                | 1 11.0.5%]                        | 15 5 (2.46)                              |
| Tumour lysis symdrome                                                                                            |                                   |                                          |
| Hyperkalaemia                                                                                                    | 0                                 | 3 J.1.41                                 |
| Dehydration Hypephosohataemia                                                                                    | 0                                 | J.1.0%] 2 1.1.0%]                        |
| Necplasms benign, maligmant amd                                                                                  |                                   |                                          |
| unspegified (incl cysts and polyps) Total nuber of patients with                                                 |                                   |                                          |
| at least one adverse event Total number of events                                                                | 9                                 | 17 3 (1.4)                               |
| Squamous cell carcinoma Colorectal cancer                                                                        | 1 J.0.58] 0                       | J..1.061                                 |
| Myelodysplastic symdrome Lung neoplasm maligmant                                                                 | 0 2 1.1.1)                        | [o\"TT z 0                                |
| Gastrointestinal disorders Totalnumber ofpatientswith at least one adverse event Total nuber of events Tiarrhoea | 4 0                               | 13 3J.1.4%1                              |
| site. conditions Total number of patients with at least one adverse event Total nuber of events Pyrexia          | 20                                | 8                                        |
| General disorders and administration                                                                             |                                   |                                          |
|                                                                                                                  | 13 1..6..9)                       | 5(2.4%)                                  |
| Camdiac disorders                                                                                                |                                   |                                          |
| Total number of patients with at least one adverse event Total nunber of events Myocardial infarction            | 3 0                               | 5 2 1.1.0%]                              |
| Injury. poisoning and procedural coplications                                                                    |                                   |                                          |
| Total number of patients with at least one adverse event Total number of events                                  | 9 6J.3.24]                        | 3 1(0.5%)                                |
| Infusionrelatedreactiom Vascular disorders                                                                       | 8                                 | 1 0                                      |
| Total number of patients with At least one adverse event Total number of events Hypotension                      | 5.2.7)                            |                                          |

<div style=\"page-break-after: always\"></div>

Tumour lysis syndrome: Six cases (3%) of TLS were reported in the V+R arm of MURANO, in one case due to a high starting dose, 100 mg instead of 20 mg.  All events occurred during the venetoclax ramp-up period and resolved within 2 days.  All 6 patients reached the recommended dose of 400 mg. In addition there were two clinical cases not meeting the Howard criteria (laboratory), 1 case in each arm of the study (BR and V+R).  No clinical TLS cases were reported in the V+R arm under the current prophylactic and monitoring measures.

Only based on Howard criteria, there were an additional 5 patients in the V+R arm with TLS, but according to the investigator not clinically relevant and not reported as AE. Three of the 5 patients were receiving the former measures for TLS prophylaxis.  Four of the 5 patients had abnormal single or multiple laboratory values at baseline, prior to starting venetoclax treatment.

There were two cases of TLS in the BR arm.

Grade 3 or higher events of infections or serious infections: These events were reported in similar frequencies in the VT and BR arms, pneumonia being the most common serious event (about 8%).

There were 4 fatal events in the VR arm, thereof 2 at time of disease transformation (Richter) and 4 in the BR group. In the BR group there were two fatalities due to opportunistic infections (Listeria, Scedosporium).

Table 23: Second primary malignancies (May 2017):

<!-- formula-not-decoded -->

<!-- image -->

|                | Primary Analysis (08 May 2017)   | Primary Analysis (08 May 2017)   | Updated Analysis (08May 2018)   | Updated Analysis (08May 2018)   |
|----------------|----------------------------------|----------------------------------|---------------------------------|---------------------------------|
|                | BR (N =188)                      | V+R (N = 194)                    | BR (N =188)                     | V+R (N =194)                    |
| Second Primary | 13 (6.9%)                        | 21 (10.8%)                       | 16 (8.5%)                       | 25 (12.9%)                      |
| Malignancies   |                                  |                                  |                                 |                                 |

Richter transformation : In the MURANO study there were 6 cases of transformation in the VR arm (DLBCL 5, Hodgkin 1) and 5 in the BR arm (DLBCL 3, Non-B cell lymphoma 1, transformation NUD 1).

Drug induced liver injury : No case fulfilling the criteria for DILI was identified in the VR arm (MURANO).

Hy's law : Two cases in the BR arm (MURANO)

Grade ≥3 Infusion-related Reactions : Overall, 6/194 patients (3.1%) in the V+R arm experienced 7 Grade ≥ 3 IRRs and 18/188 patients (9.6%) in the BR arm experienced 22 Grade ≥ 3 IRRs. The majority of these were Grade 3 in severity (7/7 events in the V+R arm; 21/22 events in the BR arm). One Grade 4 infusion related reaction was reported in the BR arm. There were no Grade 5 IRRs.

<div style=\"page-break-after: always\"></div>

In the VR arm, 1 patient experienced a serious Grade ≥3 infusion related reaction. The event resolved after 2 days following treatment for the event. Of the 6 patients in the VR arm who experienced a Grade ≥3 IRR, none discontinued rituximab treatment or had a rituximab dose modification.

In the BR arm, 9 patients experienced a serious Grade ≥ 3IRR. Of the 18 patients in the BR arm with a Grade ≥3 IRR, 3 patients discontinued rituximab treatment and 2 patients discontinued bendamustine. Additionally, 5 patients in the BR arm had a rituximab dose interruption due to a Grade ≥ 3 IRR.

## Laboratory findings

## Haematology

During the study most patients in both treatment arms either exhibited no shift or a worsening by 1 grade in any particular hematology laboratory parameter and there was no marked difference between the V+R and BR treatment arms with regards to the number of patients experiencing a shift from baseline in their haematology laboratory parameters. An exception was neutrophil count (hypo) where patients in the V+R arm who started with neutropenia at baseline were observed to experience a shift to a worse grade during treatment.

## Blood Chemistry

During the study most patients in both treatment arms either exhibited no shift or a worsening by 1 grade and there was no marked difference between the VR and BR treatment arms.

The only exception was Grade 3/4 low phosphorus values which were reported in 30/194 patients (15.5%) of patients in the V+R arm and 8/188 patients (4.3%) of patients in the BR arm.

## Safety in special populations

Age : Higher rates of SAEs in the VR arm were observed in patients ≥65 years of age as compared to patients &lt; 65 years (51.5% vs. 41.2%) (serious neoplasms (11.3% vs. 2.1%) and serious gastrointestinal disorders (8.2% vs. 1.0%).

There were no differences in the pattern of AEs between male and female patients.

## Discontinuation due to adverse events

A numerically higher rate of treatment withdrawals of any study treatment due to an AE was observed in the VR analysis sets compared with the BR analysis set, 15.7% in the VR 400 mg dose analysis set vs. 9.6% in the BR analysis set. Neutropenia, thrombocytopenia, autoimmune haemolytic anaemia, pneumonia, and malignant neoplasm progression (reported as an AE in Study M13-365) were the most frequently reported AEs ( ≥ 1% of patients) leading to discontinuation of venetoclax.

Overall, the number of patients with at least one AE leading to venetoclax dose interruption was 141/210 (67.1%) in the VR 400 mg dose analysis set. The most frequent AE that resulted in venetoclax dose interruption was neutropenia (40.5%).  Other frequently reported AEs leading to dose

<div style=\"page-break-after: always\"></div>

interruption included diarrhoea (4.8%), thrombocytopenia (4.3%), pneumonia and nausea (3.8% each), URTI (3.3%), neutrophil count decreased (2.9%), and bronchitis and influenza (2.4% each).

## Post marketing experience

No additional safety signal identified. World-wide cumulative exposure: 778 patient-treatment years.

## 2.5.1. Discussion on clinical safety

The addition of rituximab to venetoclax results, as expected, in an increase in haematological toxicity. Especially neutropenia led to interruption and sometimes dose reduction. CLL per se is associated with an increase in infectious events and the increase is of similar magnitude as seen for BR.

The overall safety profile of Venclyxto is based on data from 490 patients with CLL treated in clinical trials with venetoclax in combination with rituximab or as monotherapy. The safety analysis included patients from one phase III study (MURANO), two phase 2 studies (M13-982 and M14-032), and one phase 1 study (M12-175). MURANO was a randomised, controlled trial in which 194 patients with previously treated CLL received venetoclax in combination with rituximab. In the phase 2 and phase 1 studies, 296 patients with previously treated CLL, which included 188 patients with 17p deletion and 92 patients who had failed a B-cell receptor pathway inhibitor were treated with venetoclax monotherapy (see section 5.1).

In the open-label, randomised phase III study (MURANO), the incidence of TLS was 3% (6/194) in patients treated with venetoclax + rituximab. After 77/389 patients were enrolled in the study, the protocol was amended to incorporate the current TLS prophylaxis and monitoring measures described in Posology (see section 4.2). All events of TLS occurred during the venetoclax dose-titration phase and resolved within two days. All six patients completed the dose titration and reached the recommended daily dose of 400 mg of venetoclax. No clinical TLS was observed in patients who followed the current 5-week dose-titration schedule and TLS prophylaxis and monitoring measures (see section 4.2). The rates of grade ≥3 laboratory abnormalities relevant to TLS were hyperkalemia 1%, hyperphosphatemia 1%, and hyperuricemia 1%.

Neutropenia is an identified risk with Venclyxto treatment. Grade 3 or 4 neutropenia has been reported in patients treated with venetoclax in the combination study with rituximab (GO28667/MURANO) and in the monotherapy studies (see section 4.8). In the MURANO study, neutropenia was reported in 61% (all grades) of patients on the venetoclax + rituximab arm. Forty-three percent of patients treated with venetoclax + rituximab experienced dose interruption and 3% of patients discontinued venetoclax due to neutropenia. Grade 3 neutropenia was reported in 32% of patients and grade 4 neutropenia in 26% of patients. The median duration of grade 3 or 4 neutropenia was 8 days (range: 1-712 days). With venetoclax + rituximab treatment, febrile neutropenia was reported in 4% of patients, grade ≥3 infections in 18%, and serious infections in 21% of patients.

The most commonly occurring adverse reactions (≥20%) of any grade in patients receiving venetoclax in the combination study with rituximab were neutropenia, diarrhoea, and upper respiratory tract infection. In the monotherapy studies, the most common adverse reactions were neutropenia/neutrophil count decreased, diarrhoea, nausea, anaemia, fatigue, and upper respiratory tract infection.

<div style=\"page-break-after: always\"></div>

The most frequently reported serious adverse reactions (≥2%) in patients receiving  venetoclax in combination with rituximab or as monotherapy were pneumonia, febrile neutropenia, and TLS.

Richter transformation, in clinical practice observed as rapid progression of transformed lymphoma is expected and was observed in similar incidence in VR and BR.

Second primary malignancies were observed and should be further characterised in relation to duration of exposure and observation, etc. A numerical increase is observed also in the update in the MURANO study and appears driven by non-melanoma skin cancer. Second primaries should remain an important potential risk in the RMP. The likely magnitude of the potential risk does not influence the risk assessment to an important degree.

Discontinuations due to adverse reactions occurred in 16% of patients treated with the combination of venetoclax and rituximab in the MURANO study. In the monotherapy studies with venetoclax, 9% of patients discontinued due to adverse reactions.

Dosage reductions due to adverse reactions occurred in 15% of patients treated with the combination of venetoclax and rituximab in the MURANO study and 12% of patients treated with venetoclax in the monotherapy studies.

In the MURANO study, dose interruptions due to adverse reactions occurred in 71% of patients treated with the combination of venetoclax and rituximab. The most common adverse reaction that led to dose interruption of venetoclax was neutropenia (43%).

Tolerability of 6 cycles of VR as measured by discontinuation and AEs seems to be similar to 6 cycles BR. Monotherapy for 18 months is associated with 7% AEs leading to withdrawal.

Relevant amendments have been introduced in section 4.4 and 4.8 of the SmPC.

## 2.5.2. Conclusions on clinical safety

No new safety concerns related to venetoclax have been identified and add-on of rituximab leads to the expected increase in bone marrow toxicity.

The CHMP considers the following measures necessary to address issues related to safety:

- The submission of the final CSR from Study GO28667 (MURANO) in order to have an update on the overall safety profile with a special focus on the issues of Richter's transformation and secondary primary malignancy.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The CHMP endorsed the Risk Management Plan version 3.3 with the following content:

<div style=\"page-break-after: always\"></div>

## Safety concerns

Summary of the safety concerns:

| Summary of Safety Concerns   | Summary of Safety Concerns                                                                                                                       |
|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | • Tumor lysis syndrome • Neutropenia • Serious infection                                                                                         |
| Important potential risks    | • Embryofetal toxicity • Medication error • Richter's transformation • Second primary malignancy                                                 |
| Missing information          | • Carcinogenicity studies • Safety in severe hepatic impairment • Safety in severe renal impairment • Safety in long-term exposure (> 12 months) |

## Pharmacovigilance plan

Summary Table of Additional Pharmacovigilance Activities

| Study Name Status                                                                                                                                                                                                             | Summary of Objectives                                                                                                                                                                                                      | Safety Concerns Addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due Dates                                                                                                                                                                                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                    | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 |
| Not applicable                                                                                                                                                                                                                | Not applicable                                                                                                                                                                                                             | Not applicable                                                                                                                                                                                                             | Not applicable                                                                                                                                                                                                             | Not applicable                                                                                                                                                                                                             |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances    | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| Study M14-032 A Phase 2 Open-label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukaemia Subjects with Relapse or Refractory to B-cell Receptor Signaling Pathway Inhibitor Therapy Ongoing | Assess the efficacy and safety of venetoclax monotherapy in subjects with CLL relapsed after or refractory to treatment with ibrutinib or idelalisib                                                                       | Safety in long-term exposure (> 12 months) of venetoclax Second primary malignancy and Richter's transformation in longer exposure to venetoclax monotherapy                                                               | Interim CSR                                                                                                                                                                                                                | March 2018                                                                                                                                                                                                                 |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                 | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| Study GO28667 (MURANO) Multicenter, Phase III, Open-Label, Randomised Study in Relapsed / Refractory Patients with Chronic Lymphocytic Leukaemia to Evaluate the Benefit of venetoclax                                        | Evaluate the safety and efficacy of venetoclax and rituximab compared with BR in subjects with R/R CLL                                                                                                                     | Overall safety profile (provide comparator data) Richter's                                                                                                                                                                 | Primary analysis and interim CSR completed                                                                                                                                                                                 | Decemb er 2017                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Study Name Status                                                                                                                                                                          | Summary of Objectives                                                                                                                                                       | Safety Concerns Addressed                                                                                                                                    | Milestones   | Due Dates       |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----------------|
| (GDC-0199/ ABT-199) Plus Rituximab Compared with Bendamustine Plus Rituximab Ongoing                                                                                                       |                                                                                                                                                                             | transformation and secondary primary malignancy                                                                                                              | Final report | Decemb er 2022  |
| Study M13-982 A Phase 2 Open-Label Study of the Efficacy of ABT-199 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukaemia Harboring the 17p Deletion Ongoing               | Evaluate the efficacy of venetoclax monotherapy in subjects with R/R CLL in the presence of 17p del or TP53 mutations                                                       | Safety in long-term exposure (> 12 months) of venetoclax Second primary malignancy and Richter's transformation in longer exposure to venetoclax monotherapy | Interim CSR  | June 2018       |
| Study M12-175 A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukaemia and Non-Hodgkin Lymphoma Ongoing | Assess the safety profile; characterize PK; determine MTD, RPTD, and lead-in period regimen of venetoclax monotherapy in subjects with R/R CLL (Arm A) or NHL (Arm B)       | Safety in long-term exposure (> 12 months) of venetoclax Second primary malignancy and Richter's transformation in longer exposure to venetoclax monotherapy | Interim CSR  | Septem ber 2019 |
| Study M15-342 A Study to Evaluate the Safety and Pharmacokinetics of a Single Dose of Venetoclax in Female Subjects with Mild, Moderate, or Severe Hepatic Impairment Ongoing              | To assess the safety and pharmacokinetics of venetoclax following oral administration of a single dose of venetoclax in subjects with various degrees of hepatic impairment | Use in patients with severe hepatic impairment                                                                                                               | Final CSR    | Decemb er 2018  |

<div style=\"page-break-after: always\"></div>

| Study Name Status                                                                                                                                               | Summary of Objectives                                                                                                                              | Safety Concerns Addressed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Milestones               | Due Dates                                                               |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|-------------------------------------------------------------------------|
| Study P16-562 Prospective Observational Cohort Study to Assess the Safety of Venetoclax in the Swedish Cohort of Chronic Lymphocytic Leukaemia Patients Planned | To characterize long term safety of venetoclax including determining the incidence of select adverse events in CLL patients exposed to venetoclax. | Safety in long-term exposure (> 12 months) of venetoclax Select list of adverse events: • Second primary malignancies • Richter's transformation (DLBCL, HL) • Opportunistic serious infections • Autoimmune hematological event o Other autoimmune hemolytic anemia o Idiopathic thrombocytop enic purpura • Tumor Lysis syndrome • Hematologic adverse event o Anemia o Thrombocytop enia o Neutropenia • Pneumonia • Febrile Neutropenia • Diarrhea • Nausea/Vomit • Upper respiratory tract infection • Fatigue • Hyperphosphatemi a • Constipation | Interim CSR Final report | Every second year over a study period of 8 years Planned Decemb er 2025 |
| Study M16-185 Clinical drug-drug interaction study                                                                                                              | Open-label study to assess the effect of venetoclax on the pharmacokinetics of oral                                                                | Potential DDIs with oral contraceptives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Study planned            | Date for submiss ion cannot                                             |

<div style=\"page-break-after: always\"></div>

| Study Name Status                  | Summary of Objectives                            | Safety Concerns Addressed   | Milestones   | Due Dates                                                                                                                                 |
|------------------------------------|--------------------------------------------------|-----------------------------|--------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| with an oral contraceptive Planned | contraceptive in hematologic malignancy patients |                             |              | be specifie d since the Agency agreed to conduct ion of this study when the indicati on is potentia lly widene d to a younger populati on |

## Risk minimisation measures

Summary Table of Pharmacovigilance Activities and Risk Minimization Activities by Safety Concern

| Safety Concern             | Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                         | Pharmacovigilance Activities                                                                                                                                                  |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Tumor lysis syndrome (TLS) | Routine risk minimization measures: SmPC sections 4.2;4.4;4.5;4.8 Other routine risk minimization measures: • Prescription only medicine • Use of treatment should be initiated and supervised by specialists • Packaging design and language to facilitate adherence to the dose titration schedule • Package leaflet Additional risk minimization measures: None | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: AE follow-up questionnaire for TLS Additional pharmacovigilance activities: None |
| Neutropenia                | Routine risk minimization measures:                                                                                                                                                                                                                                                                                                                                | Routine pharmacovigilance activities beyond adverse                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Safety Concern       | Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                     | Pharmacovigilance Activities                                                                                                                                             |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                      | SmPC sections 4.2;4.4;4.8 Other routine risk minimization measures: • Prescription only medicine. • Use of treatment should be initiated and supervised by specialist • Package leaflet Additional risk minimization measures: None                                                                                                                                            | reaction reporting and signal detection: None Additional pharmacovigilance activities: None                                                                              |
| Serious infection    | Routine risk minimization measures: SmPC sections 4.2;4.4;4.5;4.8 Other routine risk minimization measures: • Prescription only medicine • Use of treatment should be initiated and supervised by specialist • Package leaflet Additional risk minimization measures: None                                                                                                     | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: Questionnaire for infections Additional pharmacovigilance activities: None  |
| Embryofetal toxicity | Routine risk minimization measures: SmPC sections 4.6; 5.3 Other routine risk minimization measures: • Prescription only medicine • Use of treatment should be initiated and supervised by specialists • Package leaflet Additional risk minimization measures: None                                                                                                           | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: Questionnaire for pregnancies Additional pharmacovigilance activities: None |
| Medication error     | Routine risk minimization measures: SmPC sections 4.2;4.9 Other routine risk minimization measures: • Prescription only medicine • Use of treatment should be initiated and supervised by specialists • Each carton will be dispensed weekly to the patient during the first 4 weeks of the dose titration • Labeling and packaging layout (immediate and outer packaging) has | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None                          |

<div style=\"page-break-after: always\"></div>

| Safety Concern                      | Risk Minimization Measures                                                                                                                                                                                                                   | Pharmacovigilance Activities                                                                                                                                                               |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                     | been designed to minimize medication errors • Package leaflet Additional risk minimization measures: None                                                                                                                                    |                                                                                                                                                                                            |
| Richter's transformation            | Routine risk minimization measures: SmPC sections 4.2 Other routine risk minimization measures: • Prescription only medicine • Use of treatment should be initiated and supervised by specialist Additional risk minimization measures: None | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional Pharmacovigilance Activities: Studies GO28667 (MURANO), M14-032, M13-982, and |
| Second primary malignancy           | Routine risk minimization measures: None • Other routine risk minimization measures: Prescription only medicine • Use of treatment should be initiated and supervised by specialist Additional risk minimization measures: None              | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: Additional Pharmacovigilance Activities: Studies M14-032, M13-982, M12 175 and P16-562.       |
| Carcinogenicity studies             | Routine risk minimization measures: SmPC section 5.3 Other routine risk minimization measures: • Prescription only medicine • Use of treatment should be initiated and supervised by specialists Additional risk minimization measures: None | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None                                            |
| Safety in severe hepatic impairment | Routine risk minimization measures: SmPC section 4.2                                                                                                                                                                                         | Routine pharmacovigilance activities beyond adverse reaction reporting and signal                                                                                                          |

<div style=\"page-break-after: always\"></div>

| Safety Concern                              | Risk Minimization Measures                                                                                                                                                                                                                                     | Pharmacovigilance Activities                                                                                                                                                                    |
|---------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                             | Other routine risk minimization measures: • Prescription only medicine • Use of treatment should be initiated and supervised by specialists • Package leaflet Additional risk minimization measures: None                                                      | detection: None Additional Pharmacovigilance Activities: Study M15-342                                                                                                                          |
| Safety in severe renal impairment           | Routine risk minimization measures: SmPC section 4.2 Other routine risk minimization measures: • Prescription only medicine • Use of treatment should be initiated and supervised by specialists • Package leaflet Additional risk minimization measures: None | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional pharmacovigilance activities: None                                                 |
| Safety in long- term exposure (> 12 months) | Routine risk minimization measures: SmPC section 5.1 Other routine risk minimization measures: • Prescription only medicine • Use of treatment should be initiated and supervised by specialists Additional risk minimization measures: None                   | Routine pharmacovigilance activities beyond adverse reaction reporting and signal detection: None Additional Pharmacovigilance Activities: Studies M14-032, M13-982, M12-175, and Study P16-562 |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC have been updated.  The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The condition for which Venclyxto in combination with rituximab is applied for is the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.

Based on single arm studies showing impressive activity in hard to treat patients with CLL, Venclyxto is currently licensed for:

- The treatment of CLL in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.
- Venclyxto monotherapy is indicated for the treatment of CLL in the absence of 17p deletion or TP5 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.

## 3.1.2. Available therapies and unmet medical need

Current treatments for CLL are not curative. Fewer patients obtain responses with each subsequent regimen, and subjects become increasingly resistant to available therapy. Patients who relapse after a disease-free period of over 1 year (2-3 years for chemoimmunotherapy) are considered treatment sensitive and may be candidates for treatment reinitiation. Patients who relapse after a shorter interval, or are refractory to first-line treatment, present a more challenging group, particularly those who are older, have comorbid conditions, and/or harbour high-risk cytogenic abnormalities. Overall, there is a long expected survival (from time of diagnosis, 5-year relative survival rate about 75%). In the EUROCARE-5 registry, the survival rate for patients with CLL at 5 years post diagnosis was 69.0%. Due to the licensure of highly active new treatment options (venetoclax, ibrutinib, idelalisib), therapy in B-cell malignancies is in a dynamic phase.

## 3.1.3. Main clinical studies

The MURANO study was a randomised study comparing bendamustine + rituximab (BR) with venetoclax + rituximab (VR), both for six cycles followed by venetoclax versus no treatment up to a total study duration of 2 years in R/R CLL after at least one, but not more than three lines of therapy, thereof at least one 'guideline compliant' regimen.

The MA of Venclyxto was conditional to the reporting of study M14-032, whilst reporting of the current study MURANO was an annex IIE obligation.

## 3.2. Favourable effects

The primary endpoint (ITT), PFS, showed a HR 0.17, with event rates 59% for the BR arm and 17% in the VR arm, p&lt; 0.0001 (investigator assessment). At an updated efficacy analysis with all patients off treatment (data cut-off date 8 May 2018 and median follow-up of 36 months) the 36-month PFS

<div style=\"page-break-after: always\"></div>

estimate in the venetoclax + rituximab arm was 71.4% [95% CI: 64.8, 78.1] and in the bendamustine + rituximab arm was 15.2% [95% CI: 9.1, 21].

The observed PFS benefit of venetoclax + rituximab  compared with bendamustine + rituximab was consistently observed across all subgroups of patients evaluated, including age (&lt; 65, ≥ 65 years and &lt; 75, ≥ 75 years), prior lines of therapy (1, &gt;1), bulky disease (&lt; 5 cm, ≥ 5 cm), 17p deletion, 11q deletion, TP53 mutation , IgVH mutation, and refractory versus relapse to most recent therapy.  The HR for PFS (17p del) was HR 0.13, event rates 59% (BR) and 15% (VR) p&lt; 0.0001 (investigator assessment) (predefined subgroup).

With regard to the secondary endpoint CR+Cri (hierarchical testing), this was 3.6% (BR) vs. 8.2% (VT), p=0.08 (IRC).

Efficacy results for the pre-specified primary analysis (data cut-off date 8 May 2017) were also assessed by an Independent Review Committee (IRC) demonstrating a statistically significant 81% reduction in the risk of progression or death for patients treated with venetoclax + rituximab (hazard ratio: 0.19 [95% CI: 0.13, 0.28]; P&lt;0.0001). Median DOR was not reached with median follow up of approximately 23.8 months.

## 3.3. Uncertainties and limitations about favourable effects

Additional information on the long term outcome, would be needed as OS is still immature (20% and 11% events). The exploratory HR was 0.5 (0.3; 0.85). Data  will be obtained through the final CSR of MURANO study (see RMP).

## 3.4. Unfavourable effects

The safety profile of VR is manageable in the clinic with standard measures and adherence to Venclyxto (see SmPC section 4.2). Dose reductions/interruptions, mainly for neutropenia, were undertaken in about 2/3 patients. In the combination phase, neutropenia was also more pronounced in the VR arm. There was no difference in infectious events.

The most commonly occurring adverse reactions (≥20%) of any grade in patients receiving venetoclax in the combination study with rituximab were neutropenia, diarrhoea, and upper respiratory tract infection. The most frequently reported serious adverse reactions (≥2%) in patients receiving venetoclax in combination with rituximab or as monotherapy were pneumonia, febrile neutropenia, and TLS.

Altogether 16% discontinued the combination phase and 9% the monotherapy phase.

Second primary malignancies are included in the RMP as an important potential risk that should be monitored.

<div style=\"page-break-after: always\"></div>

## 3.5. Uncertainties and limitations about unfavourable effects

## 3.6. Effects Table

Table 24: Effects of venetoclax

| Effect                 | Short description      | Unit                 | Treatment            | Control              | Uncertainties / Strength of evidence                                     | References           |
|------------------------|------------------------|----------------------|----------------------|----------------------|--------------------------------------------------------------------------|----------------------|
| Favourable Effects     | Favourable Effects     | Favourable Effects   | Favourable Effects   | Favourable Effects   | Favourable Effects                                                       | Favourable Effects   |
| PFS                    | Primary endpoint       | HR 0.19 P<0.0001     |                      |                      | Updated analyses indicate that the event pattern is comparable VR vs. BR |                      |
| CR                     | First secondary e.p.   | %                    | 8                    | 4                    | IRC analysis (see above)                                                 |                      |
| OS                     | Immature               | HR 0.5 (0.3; 0.85)   | Events 11%           | Events 20%           |                                                                          |                      |
| Unfavourable Effects   | Unfavourable Effects   | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                     | Unfavourable Effects |
| Discontinuation of any | Discontinuation of any | %                    | 10                   | 8                    |                                                                          |                      |
| AE with fatal outcome  | AE with fatal outcome  | %                    | 6                    | 5                    |                                                                          |                      |
| SAE                    | SAE                    | %                    | 46                   | 43                   |                                                                          |                      |

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

B-cell malignancies is in a dynamic phase as highly active new treatment options (venetoclax, ibrutinib, idelalisib), are approved. Licensure was conditional to the reporting of study M14-032, whilst reporting of the current study MURANO was an annex IIE obligation.

In studies comparing induction + maintenance vs. induction only, endpoints beyond first time to progression or deaths are expected to support licensure according to the current NfG. In this case an established standard of care regimen (BR) over 6 months is compared with an experimental regimen (VR) over 2 years, i.e. two regimens of different durations were compared. This may justify a partly different approach from an assessment perspective, not least as CLL is an indolent disease with durable responses also in the R/R stage and beyond.

In the interim analysis submitted to support licensure of the VR regimen, the primary endpoint and all supportive measures of efficacy clearly indicated that VR is superior to BR. The pattern of recurrence after end of therapy in the VR arm, a highly relevant outcome measure from a clinical perspective, provided too limited information for an assessment. Based on the update, it appears clear that the recurrence pattern off-therapy in the VR arm is not worse than the pattern in the BR. As the roughly estimated 'truncated' mean time to next line of therapy appears longer than 18 months (24 - 36 months) a benefit of VR over BR also from the perspective of 'time off-therapy' is likely, but not proven yet.

The safety profile of VR is manageable, dose reductions/interruptions, mainly for neutropenia were undertaken in about 2/3 patients. In the combination phase, neutropenia was also more pronounced in

<div style=\"page-break-after: always\"></div>

the VR arm. There was no difference in infectious events. Altogether 16% discontinued the combination phase and 9% the monotherapy phase. Altogether the intensity of treatment is rather high, but clinically clearly manageable by standard measures.

CLL in response may be viewed as an essentially symptom-free disease and next-line therapy is normally instituted in case of symptomatic disease. A delay in the initiation of next-line therapy has been shown to be achievable with an HR of 0.2, corresponding to a roughly estimated truncated mean of more than 18 months. These data are immature, and assuming that there are no major differences in duration of next-line therapies, the VR regimen despite its longer duration, is unlikely to result in a totality of more time on therapy with associated side effects than the use of BR in treatment experienced patients with CLL. At this early time point, besides the benefit of higher response rates and longer estimated PFS, OS data also look favourable to the experimental regimen.

## 3.7.2. Balance of benefits and risks

Altogether benefit - risk is found to be favourable, but there are outstanding issues that should be addressed in the final study report. Apart from updates of OS, PFS (e.g. reported as restricted mean time) and, e.g. comparative time on/off therapy, an update of MRD data is of clear interest. This may enable a more detailed analysis of pattern of recurrence in responding patients off therapy, e.g. recurrence in relation to depth of response (by quantitative data, not only dichotomized) and the possible additional relevance of study therapy.

Final safety data for the monotherapy phase will be reported (see RMP).

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable.

## 3.8. Conclusions

The overall B/R of Venetoclax in combination with rituximab in the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy is concluded to be positive.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of Indication to include Venclyxto in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 of the SmPC are updated.

The Package Leaflet is updated in accordance.

This submission also fulfils the Annex II condition to submit the results of the MURANO study comparing venetoclax plus rituximab to bendamustine plus rituximab in patients with relapsed/refractory CLL.

In addition, RMP version 3.3 (in version 2 of the RMP template) is being approved.

The variation leads to amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP).

## Conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk management plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

In addition, an updated RMP should be submitted:

<div style=\"page-break-after: always\"></div>

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Venclyxto is not similar to Arzerra (ofatumomab), Gazyvaro (obinutuzumab) and Imbruvica (ibrutinib) within the meaning of Article 3 of Commission Regulation (EC) No. 847/200. See appendix I

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Extension of Indication to include Venclyxto in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 of the SmPC are updated.

The Package Leaflet is updated in accordance.

This submission also fulfils the Annex II condition to submit the results of the MURANO study comparing venetoclax plus rituximab to bendamustine plus rituximab in patients with relapsed/refractory CLL.

In addition, RMP version 3.3 (in version 2 of the RMP template) is being approved.

The variation leads to amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP).

## Summary

Please refer to the Scientific Discussion - Venclyxto II-08.

## 6. Attachments

1. SmPC, Annex II, Package Leaflet (changes highlighted) of Venclyxto, film-coated tablets as adopted by the CHMP on 20 September 2018.

## 7. Appendix

1. CHMP AR on similarity dated 20 September 2018